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Abstract
Contusion Progression in Traumatic Brain Injury
Mathew Rhys Guilfoyle
Cerebral contusions that result from brain trauma have the propensity to enlarge over the days
following injury, including extension of the haemorrhage core and swelling of the surrounding
peri-contusional brain. This secondary injury increases the likelihood of death and severe disabil-
ity, and interventions to prevent or limit contusion progression may improve clinical outcomes.
In preclinical studies a number of pathophysiological process have been identified that contribute
to brain oedema including blood brain barrier (BBB) disruption, neuroinflammation, and cerebral
metabolic dysfunction. This work has set out to measure and quantify contusion progression in
TBI patients, characterise BBB permeability with computed tomography imaging, and identify
key mediators of this process using intracerebral microdialysis.
• Study I: A robust and effective stereological method for measuring the volume of brain
lesions was validated and applied to a cohort of TBI patients to examine the temporal course
of contusion progression. Intracranial pressure and brain lactate/pyruvate ratio were found
to be associated with the magnitude of contusion expansion.
• Study II: Dynamic contrast enhanced computed tomography (DCE-CT) was applied in pa-
tients with brain contusions to quantify BBB permeability. The imaging showed profound
reduction in cerebral blood flow associated with contusions but did not show evidence of
contrast extravasation or BBB permeability.
• Study III: Paired microdialysis catheters, one inserted in proximity to a contusion and an-
other in non-injured brain, were used to characterise the peri-contusional inflammatory
response with a multiplex assay of 42 cytokines, chemokines, and growth factors. Peri-
contusional tissue was found to exhibit an early pro-inflammatory signature.
iii
• Study IV: A paired microdialysis study of pericontusional expression of matrix metallopro-
teinases (MMP). Specific increase in the expression of MMP-9 was identified in pericontu-
sional brain
• Study V: Nitric oxide (NOx) concentrations were assayed in pericontusional and uninjured 
brain with paired microdialysis. NOx levels were lower in pericontusional brain and exhib-
ited significant correlations with brain glucose, pyruvate, and lactate.
• Study VI: Microdialysis data from 619 TBI patients with collated to explore the physiolog-
ical correlates of deranged metabolism and elevated LPR. Cerebral glucose was found to a 
key determinant of LPR.
The implications of these findings in the context of existing knowledge of BBB permeability, in-
flammation, and cerebral metabolism in TBI are discussed. Future investigations to clarify the
mechanisms highlighted, and potential therapeutic studies directed at reducing contusion pro-
gression and brain oedema are suggested.
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Chapter 1
General Overview
1.1 Traumatic Brain Injury
1.1.1 Incidence and Outcome
Traumatic Brain Injury (TBI) remains the leading cause of death and disability amongst young
people (i.e age <40 years), and the annual incidence has continued to increase over the last
decade1. In the UK in 2014-15, TBI was the principal cause for over 175,000 admissions to hospital
and necessitated around 5000 intensive care unit (ICU) admissions.
Mortality for patients presenting with severe TBI i.e. Glasgow Coma Score (GCS) <8, is 20-40%
[168, 55, 139] Furthermore, 50-70% of patients survive with significant cognitive and physical
disability [139]. Together these result in TBI having major social and economic impact, both for
patients themselves and their families and relatives, and there is a self-evident motive for con-
tinued investigation into understanding the pathophysiology of TBI and identifying therapeutic
strategies to improve outcomes.
1.1.2 Primary vs. Secondary Injury
The neurological outcome from TBI is determined both by the severity of the primary injury i.e.
the degree of immediate irreversible axonal disruption and cell loss due to mechanical forces at
the time of impact, and the ensuing secondary insults that exacerbate the extent of tissue destruc-
tion over the subsequent hours and days. The major secondary insults that are known to impact
1UK Hospital Episode Statistics http://www.hscic.gov.uk; useful summary by the Headway TBI support
group: https://www.headway.org.uk/media/2881/brain-injury-statistics-methodology-injury-categories-and-further-
notes.pdf
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CHAPTER 1. GENERAL OVERVIEW
on survival and functional outcome include systemic hypotension and hypoxia, raised intracra-
nial pressure, and cerebral dysautoregulation, all of which ultimately result in inadequate tissue
perfusion and ischaemia [35, 91]. Current medical and surgical management of severe TBI is fun-
damentally based on maintaining these parameters within normal physiological ranges during
the first several days following injury when the traumatised brain is particularly vulnerable. In
particular, avoidance of raised intracranial pressure (ICP) and reduced cerebral perfusion pres-
sure (CPP) is the key target of modern goal-directed tiered neurocritical care protocols, involving
escalation of increasingly intensive medical treatment and, ultimately, surgical decompressive
craniectomy for patients with refractory intracranial hypertension (Fig 1.1).
Within the fixed confines of the skull the principal variables that contribute to intracranial pres-
sure, in the context of TBI, are extra- and intra-axial mass lesions (i.e. extradural, subdural or
intraparenchymal haematomas), hydrocephalus, cerebral blood volume, and the accumulation of
brain water content distributed between the interstitial and intracellular spaces as different forms
of cerebral oedema. The latter of these factors is the most challenging to directly treat. Mass
lesions and hydrocephalus can be rectified with surgery, and intracranial blood volume can be,
within limits, readily manipulated through control of ventilation and arterial CO2 tension. In
contrast, brain oedema may be refractory to all interventions [177].
1.2 Cerebral Contusions and Brain Oedema
Around 8% of all TBI patients and over a third of those with severe TBI have haemorrhagic
parenchymal mass lesions or contusions [81]. Concomitant with the disruption of neurons and
glia the transfer of kinetic energy at the moment of impact causes shearing of microvessels and
extravasation of blood. Exposure of intracellular substances and the products of early cellular
necrosis are key instigators of a multitude of secondary injury processes which, although rep-
resenting highly conserved ’normal’ responses to injury, frequently have deleterious effects on
cells and tissues that survived the primary injury [96]. Breakdown products from haemolysis
of extravasated erythrocytes are also highly toxic to neurons and other CNS cells, via both exci-
toxic and haem-dependent mechanisms [167]. Furthermore, microvascular rupture also results in
localised loss of tissue perfusion and ischaemia, further compounding secondary injury within
surrounding pericontusional tissue.
Consequences of continued microvascular disruption and dysfunction include further escape of
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If ICP >20 mmHg 
escalate to STAGE 2, 
consider rescan and 
evacuation of SOL
Patients with traumatic brain injury admitted to NCCU are managed according to this protocol. Each step of the protocol must be 
preceded by thorough check of the position and accuracy of all intracranial monitoring. Surgical referral for evacuation of 
significant space occupying lesions (SOL) is mandatory before escalating medical treatment. Consider EVD insertion before 
escalating medical treatment. All patients must have the following within 4h of admission to NCCU:
1) Invasive arterial (transducer at tragus) and central venous catheter 
2) ICP monitoring
3) Cerebral microdialysis catheter and PbO2 probe
4) ICM+
Initial target CPP of 65mmHg (CPP > 55mmHg may be acceptable). Autoregulation parameters and brain biochemistry are used to 
individualise targets. 
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ICP/CPP Algorithm for Neurosciences and Trauma Critical Care
Stage 1
Adequate resuscitation, ensure euvolemia, add inotropes and vasopressors if needed. FICE echo.
Elevate head to 30° unless clinically contraindicated (otherwise 10-15°)
SpO2 >94%; PaCO2 4.5 – 5.0kPa
CPP 55 - 65 mmHg – transducer at tragus. 
Hb >90
Blood glucose 4 - 10mmol/l; (brain glucose >0.5mmol/l)
Multimodal monitoring: PRx <0.2 (use CPPopt); PbO2 >15; LPR <25
Targeted temperature management to 37°C (regular paracetamol + cooling); 
Propofol 2 - 5mg/kg/hr; fentanyl 1 - 4 micrograms/kg/hr; consider atracurium 0.5mg/kg/hr. 
AED if seizures suspected (first line – levetiracetam – 1g IV OD; second line – phenytoin 20mg/kg IV 
loading then 100 mg IV TDS); EEG
Stage 2
Drain CSF – EVD at 5 - 10 cmH2O
5% NaCl 2ml/kg IV (until plasma Na >160 mmol/l or plasma osmolality  320 mOsm/Kg)
Mild hypothermia, temp 35°C, daily lipids, ECG and CK if still on propofol
Stage 3
Trial of CPP >70mmHg
Advanced haemodynamic monitoring – further optimise cardiovascular function
AED if not already initiated
Daily lipids, ECG and CK if still on propofol
On consultant approval only: PaCO2 to 4.0 kPa and monitor brain oxygenation
Stage 4 (NCCU consultant approval only)
Moderate hypothermia to 32 – 34°C. Change to midazolam (± max 2mg/kg/hr propofol)
Daily lipids, ECG and CK
Stage 5 (NCCU consultant approval only)
Add IV anaesthetic (e.g. propofol 1mg/kg IV stat) - maintain CPP
If ICP and CPP improve, start thiopental: 250mg boluses up to 3 - 5g, then 3 - 8mg/kg/hr
Burst suppression ratio »50%
If ICP >20 mmHg 
escalate to STAGE 3, 
consider rescan and 
evacuation of SOL
If ICP >25 mmHg 
escalate to STAGE 4, 
consider rescan and 
evacuation of SOL
If ICP >25 mmHg 
escalate to STAGE 5, 
consider rescan and 
evacuation of SOL
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decompressive 
craniectomy 
(mandatory NCCU 
consultant discussion)
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Figure 1.1: Addenbrooke’s Hospital Neurocritical Care Unit (NCCU) ICP/CPP Protocol
blood in to the intersitial space, endothelial ischaemia and swelling causing microvessel throm-
bosis or occlusion, loss of integrity of the blood-brain barrier, and progressive oedema [154]. The
mass effect of an expanding volume of contusion and oedema further compromises local perfu-
sion and contribute to raised intracranial pressure affected global cerebral perfusion and hernia-
tion syndromes.
Prospective studies suggest 30-50% or more of patients develop progressive haemorrhagic injury
(PHI) manifest as a volume expansion of the core haemorrhagic lesion on serial imaging studies
[126, 122]. Typically this is also associated with concomitant increase in peri-haematoma oedema
and brain swelling, collectively contributing to reduced intracranial compliance and increased
pressure.
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PHI is predominantly an early phenomenon that occurs within the first 24 hours following in-
jury. As a corollary of this a higher incidence of PHI is observed the earlier an initial CT scan is
performed. Increased age and lower admission GCS are both independent risk factors for PHI
[126]. Larger contusions and traumatic parenchymal haematomas are also more likely to display
further progression [2]. Patients on therapeutic anticoagulation at the time of injury are at sig-
nificantly higher risk of sustaining larger extra- and intra-axial haematomas and of suffering PHI
[204]. The evidence for a similar effect of anti-platelet therapy is less concrete; aspirin therapy
alone does not appear to increase the risk of PHI. Coagulopathy on admission also predisposes
to PHI [126, 204, 53].
1.2.1 Classification of Brain Oedema
Although further expansion of the haemorrhagic contusion core can be an important component
of raised ICP, it is typically pericontusional swelling and oedema that has a more major impact
after the first 24h from injury. The mechanisms by which the brain can accumulate tissue water
and swell remain a subject of debate, no more so that which predominates in traumatic injury.
Cerebral oedema may be broadly classified as cytotoxic (cellular) or vasogenic (extracellular)(Fig
1.2) [46, 117]. Cytotoxic oedema is characterised by redistribution of water from the interstitial
to intracellular compartment as a result of osmotic imbalance, typically attributed to failure of
Na/K and other energy-dependent membrane pumps. Importantly, though cytotoxic oedema
is associated with marked cellular dysfunction, it does not produce a gain in total brain water
and therefore, by itself, cannot generate gross brain swelling or raised ICP. As the term implies,
vasogenic oedema is a shift of water from the intravascular space to the brain interstitium, and
generally entails both a degree of increased permeability of the blood-brain or brain-CSF barriers
and an osmotic or hydrostatic gradient driving water extravasation. Primary disruption of the
blood brain barrier (BBB) allows plasma macromolecules to leak into the interstitial space and
their subsequent breakdown generates an osmotic gradient and fluid shift. An alternative model
of vasogenic oedema that may be relevant in TBI has been proposed by Katayama, wherein neu-
ronal and glial cell death (e.g. in a contusion) releases intracellular molecules which produce an
osmotic gradient that draws water from plasma without gross BBB disruption.[89]
There remains longstanding controversy as to the relative importance of the different types of
cerebral oedema and the role of BBB permeability in the context of acute TBI. Early MRI stud-
ies by Marmarou and colleagues, both in animal models and TBI patients, have been interpreted
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as showing an early but transient period of BBB permeability and vasogenic oedema over the
first few hours after injury, followed by a period of several days increasing brain water content
but predominantly cytotoxic oedema reflected in reduction of the apparent diffusion coefficient
(ADC) [14, 15, 17, 82, 113]. However, ADC is a net measure of the relative magnitude of vaso-
genic and cytotoxic oedema and hence does not preclude both coexisting. Moreover, to explain
an increase in brain water content there must be flux from the intravascular to interstitial space
(i.e. vasogenic oedema) with, presumably, a secondary redistribution into the intracellular com-
partment. Significantly, in animals subject to combined TBI and a secondary injury of hypoxia
and hypotension the observed period of BBB permeability was extended. Detailed studies with
tracers of varying molecular weights in focal and diffuse TBI models have shown that BBB perme-
ability to large macromolecules is limited to the first <6 hours following injury, but that continued
opening for molecules of size 4-10kDa is observed for several days [63, 109]. Corroborating these
findings, a study of rabbits subject to TBI followed with serial dynamic contrast enhanced MRI
showed evolving permeability beginning at 3 hours and peaking at 3 days both in the lesion core
and surrounding brain [194].
Figure 1.2: Schematic representation of vasogenic and cytotoxic oedema. Adapted under Creative Commons attribution
licence from [117]
1.3 Imaging Blood Brain Barrier Permeability
All techniques for measuring or imaging BBB (dys)function share a common principle of quan-
tifying the extravasation and parenchymal accumulation of a molecule to which the brain en-
dothelium would normally be impermeable. Administration of contrast agents is routine practice
in clinical computed tomography (CT) and magnetic resonance imaging (MRI), and highlight
pathologies where the BBB is permeable (e.g. tumours or inflammatory lesions). However, with
standard imaging protocols of single pre- and post-contrast scans only a qualitative assessment
of permeability can be made. To quantify BBB permeability the time course of contrast influx
and efflux within the vasculature and tissue is required, which necessitates rapid repeated serial
imaging over the course of several minutes [28]. These imaging protocols are typically labelled as
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’dynamic’ or ’perfusion’ imaging.
Dynamic MRI with gadolinium-based contrast agents, either employing dynamic contrast en-
hancement (DCE-MRI, T1-weighted) or dynamic susceptibility contrast (DSC-MRI, T2*-weighted)
sequences are perhaps the most widely utilised imaging modalities for examining BBB permeabil-
ity [73, 182]. Standard gadolinium chelates such as Gadopentetic Acid (Gd-DTPA) have molec-
ular weight of approximately 550Da but for investigating the degree of permeability to macro-
molecules alternatives such as Gd-DTPA complexed with hyaluronic acid or dextran are avail-
able. Ultimately quantifying the permeability coefficient (usually termed K-trans) requires fitting
one of a number of alternative pharmacokinetic models to the time-course data from individual
voxels, with the Tofts and Patlak models the most commonly used [73, 182, 158].
Dynamic contrast enhanced CT (DCE-CT, often synonymously called perfusion CT) is analo-
gous to DCE-MRI and can be performed on most modern multislice CT scanners that are able
to acquire serial volume scans of the brain with sufficient temporal resolution, using standard
ionic or non-ionic iodinated contrast agents injected as a rapid bolus. Compared with MRI, the
linear relationship between CT Hounsfield unit density with contrast concentration simplifies
pre-processing of the images [182]. In general, permeability is quantified either by non-linear
optimisation of a two compartment model with a permeability term (e.g. modified Tofts model),
or employing the Patlak plot which essentially arrives at the permeability coefficient as the gra-
dient of the straight line fit to the plot of the ratio between voxel density and that in a reference
artery, against the integral of the density in the reference artery divided by the current density in
the reference artery, for all time points [158]. In addition to assessing permeability these imaging
protocols provide per-voxel quantitation of cerebral blood flow, blood volume, and other haemo-
dynamic parameters, typically through deconvolution with the arterial input function, i.e. the
time course of the contrast bolus within one of the major cerebral arteries [92].
DCE-MRI has been favoured in most clinical and research contexts given the superior anatom-
ical fidelity of MR structural imaging, the additional advanced MR sequences such as diffusion
tensor imaging that can be performed in the same imaging session, and the avoidance of ionising
radiation. However, in the context of imaging permeability in acute conditions, such as stroke
or TBI, the better availability and more rapid acquisition of CT is a potential major advantage,
particularly when patients may be imaged on a number of occasions.
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DCE-MRI and DCE-CT have shown evidence of increased permeability related to a number of
pathologies including intrinsic brain tumours (both primary and metastatic), multiple sclero-
sis plaques, infection, and small vessel disease [73, 182]. In stroke, permeability imaging has
emerged as having a number of potentially important clinical implications, specifically early in-
creases in BBB permeability identified by both DCE-MRI and DCE-CT have been found to predict
the likelihood of infarct extension, cerebral swelling, haemorrhagic transformation, and mortality
[134, 145].
In a pre-clinical diffuse impact-acceleration TBI model, dynamic MRI did not show evidence
of significant BBB permeability [18]. However, more recent studies in focal injury models have
shown regions of increased permeability in proximity to the contusion lesion, that BBB dysfunc-
tion starts within three hours of injury but progresses to reach its peak at around three days, and
that the degree of permeability correlates with final lesion volume [193, 105, 195]. Several studies
have utilised DCE-MRI to examine the prevalence of chronic changes in BBB permeability in pa-
tients with TBI of varying severity. However, there is little data on the acute temporal course and
spatial pattern of BBB permeability in human TBI patients.
1.4 Pathophysiology of Blood Brain Barrier Dysfunction Follow-
ing TBI
The blood brain barrier (BBB) is formed by the neurovascular unit, consisting of an endothelial
monolayer, basal lamina, associated support cells including pericytes and smooth muscle, and
astrocyte foot process which cover 98-99% of the vascular wall [12, 67, 106] (Fig 1.3A). Apart from
small (<400Da) lipophilic molecules, the BBB tightly regulates the exchange of all substances be-
tween plasma and the brain interstitium. Ion homeostasis and uptake into the brain of small
molecules, such as glucose and amino acids, is conducted via specific endothelial membrane
channels and solute carriers. Larger peptides and proteins are transported by endo- or transcy-
tosis pathways within caveolae and clathrin-coated microvesicles (Fig 1.3B, right). Importantly,
paracellular diffusion is highly restricted by tight junctions (TJ) between the apical regions of ad-
jacent endothelial cells which are composed of the transmembrane proteins claudin and occludin
linked to the cytoskeleton by the intracellular scaffolding proteins zona occludens (ZO)-1 to -3
[12] (Fig 1.3C).
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Brain injury may result in excess BBB permeability through increased caveolae formation and
transcytosis, or by disruption of tight junction protein expression and assembly permitting un-
regulated passive diffusion across the endothelium [106]. This latter mechanism is proposed to
play the predominant role in cerebral vasogenic oedema following TBI [154].
The temporal course of experimental BBB disruption after injury is typically biphasic, with an
immediate or early phase of hyperpermeability, followed by temporary restoration of BBB func-
tion, and subsequently a delayed and more prolonged period of opening [11, 183]. The early
period of permeability is presumed to reflect the extent of direct mechanical disruption of brain
microvessels by the primary impact. Brain parenchymal cells are then exposed to blood-borne
factors that are normally shielded from the CNS, promoting a number of inflammatory pathways
which have been implicated in the later delayed phase of BBB permeability. Exacerbating this
process is intravascular thrombosis as a consequence of endothelial disruption, which sets up a
localised ischaemic response and inflammatory signalling triggered by thrombin, which rapidly
activates astrocytes and microglia; this phenomenon has been confirmed in experimental TBI and
in human patients [146, 162]. Crucially, while the immediate transient BBB opening may be diffi-
cult to prevent, the secondary phase of permeability potentially offers a therapeutic window and
practical opportunity to intervene and limit the extent of swelling.
A plethora of intercellular signalling pathways have been reported to be involved in delayed
BBB opening (Fig 1.4). Here we have focused on a subset that have been most strongly implicated
as having pivotal roles in vasogenic oedema in TBI patients.
1.4.1 Pro-inflammatory cytokines and chemokines
In contrast to long established doctrine that the central nervous system is an immune privileged
organ, there is now widespread recognition that the brain inflammatory response to injury is
a key part of the pathophysiology of TBI, including BBB disruption. Early following TBI, pro-
totypic pro-inflammatory cytokines, such as IL-1b and TNFa, are rapidly expressed, alongside
chemokines that induce immune cell migration into the brain parenchyma. The initiators of this
cascade are disease- (or danger-) associated molecular patterns (DAMPs), which are essentially
cytosolic or nuclear proteins, nucleic acids, and other macromolecules which are exposed on the
cell surface or released into the interstitium following traumatic tissue disruption and activate
inflammatory signalling predominantly via toll-like receptors [131]. IL1b and TNFa have been
shown in vitro to promote permeability of brain endothelial cells, both by inducing cytoskeletal
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A
B
C
Figure 1.3: (A) schematic representation of cellular components of the neurovascular unit, (B) representation of the mul-
tiple regulated pathways for transport of different molecules across the healthy BBB, (C) detailed structure of
apical tight junctions and cytoskeleton, which form the primary barrier to paracellular diffusion.
changes that cause cellular retraction, downregulation of tight junction protein synthesis, and dis-
ruption of cell membrane associated with tight junctions [42, 197, 110, 104]. At least some part of
the IL-1b induced permeability may be VEGF-dependent (see below) [22, 6].
Furthermore, pro-inflammtory cytokines also initiate the upregulation of cellular adhesion molecules,
such as intercellular adhesion molecules (ICAM), vascular cell adhesion molecules (VCAM), and
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Figure 1.4: Pathways affecting BBB permeability following TBI. Adapted under Creative Commons attribution licence from
[37]
E-selectin, at the brain endothelial surface [198, 65] and increase expression of chemokines that in-
duce migration of neutrophils, monocytes, and macrophages. This latter effect is crucial as, while
there is extravasation of red blood cells in the process of early mechanical BBB disruption, there is
minimal leuocyte infiltration without the additional signalling of chemotactic factors. This, again,
suggest a potentially feasible therapeutic window in which to effect reduction in the migration of
neutrophils and macrophages that are highly toxic to neurons.
Prominent chemokines that have been implicated in TBI and other acute brain injury models
are Monocyte Chemoattractant Protein-1 (MCP-1, also known as CCL2), and MCP-3 (CCL7), and
IL-8 (CXCL8). Sustained MCP-1 expression has been assayed in CSF of TBI patients, and mice
deficient in MCP-1 have lower total lesion volume in experimental focal brain injury [148]. Corre-
spondingly, mice over-expressing CCL2 were found to have massive neutrophil recruitment into
the brain with prolonged BBB disruption [54]. The initial influx of inflammatory cells as a result
of chemokine production by astrocytes and endothelial cells, is subsequently exacerbated by fur-
ther production of chemokines by neutrophils and monocytes themselves. Further, chemokines
also amplify the severity of vasogenic oedema via a direct effect on BBB permeability through
endothelial cell actin cytoskeleton eorganisation and inhibiting expression of claudin and other
tight junction proteins [160, 161].
IL-8 is a chemokine has been shown to promote neutrophil infiltration and consequently increase
blood brain barrier permeability and may be activated upstream by IL-1b [88, 200]. Levels of IL-
8 were previously found to be markedly elevated in CSF following TBI and are associated with
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increased blood brain barrier permeability measured by serum:CSF albumin quotient [93, 196]
and the current data corroborate elevated interstitial levels. In one study IL-8 CSF concentrations
were significantly higher in subsequent fatalities [98].
1.4.2 Vascular Endothelial Growth Factor
Several lines of evidence suggest that Vascular Endothelial Growth Factor and related mediators
play a major role in the development of BBB permeability associated with a range of pathologies,
including TBI. VEGF-A through -D and Placental Growth Factor (PlGF) are key regulators of en-
dothelial proliferation and angiogenesis, and have potent effects on vascular permeability [50].
VEGF-A (usually referred to simply as VEGF) is the most prominent in the adult vascular system
and is the best characterised. VEGF-B is a regulator of embryonal vasculogenesis and VEGF-C
and ?D are involved in the development of lymph vessels. VEGFs exert their action via at least
three receptor tyrosine kinases: VEGFR1 (Flt-1), VEGFR2 (Flk-1 or KDR) and VEGFR3 (Flt-4) [50].
Alternative splicing of the primary transcript from the 8-exon VEGFA gene yields isoforms and
variants with divergent expression patterns and biological activity [50, 66]. Alternative splicing
of exons 6 and 7, the latter of which codes a heparin binding domain, produces assorted iso-
forms containing 121 to 206 residues which vary considerably in their affinity to cell membranes
and extracellular matrix (ECM). VEGF121 is acidic and freely diffusible in the extracellular space
whereas the more basic VEGF189 and VEGF206 are strongly bound to cell surface proteoglycans.
VEGF165, typically the most abundant isoform, has intermediate affinity and exists in both bound
and soluble fractions. Matrix metalloproteinases (MMPs) and other enzymes including urokinase
and plasmin can cleave bound VEGF and release active fragments that are recognised by VEGF
receptors [50].
In vitro, VEGF increases the permeability of brain microvascular endothelial cell (BMEC) mono-
layers by downregulation of tight junction proteins, including ZO-1, claudin and occludin, which
disrupts cell-cell adhesion and results in endothelial fenestrations [209, 190, 7]. In other endothe-
lial models, including brain-tumour interfaces, VEGF also increases expression of caveolin and
mobilizes exisiting calveolae, thereby increasing permeability by accelerating the transcytosis sys-
tem [31]. One of the principal upstream regulators of VEGF is hypoxia inducible factor (HIF), a
transcription factor that is stabilised under conditions of cellular hypoxia and which promotes
VEGF expression. Correspondingly, BMEC cultured under hypoxic conditions show a two-fold
increase of both VEGF and VEGFR1 expression and become hyperpermeable, an effect that is
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abolished independently by anti-VEGF antibodies and inhibitors of nitric oxide synthesis.[52]
In animal transient or permanent cerebral artery occlusion studies there is upregulation of VEGF
and VEGFR1 expression in astroglia, endothelium, and neutrophils commencing between 1-48
hours following ischaemia, dependent on the specific model parameters [95, 38], which is associ-
ated with reduced expression and proteolysis of tight junction proteins, the latter via activation
of matrix metalloproteinases (MMP-9) [59, 16]. Further, studies have demonstrated that interven-
tions to interrupt this pathway significantly attenuate permeability and cerebral oedema follow-
ing ischaemia-reperfusion in vivo, including pharmacological inhibition of HIF, sequestration of
VEGF with soluble receptors, and MMP antagonists [179, 203, 142].
Alternative pathways may activate the HIF-VEGF axis under non-hypoxic conditions. For ex-
ample, intracerebral injection of IL-1beta is associated with BBB permeability and oedema and
there is evidence from inflammatory lesion models that this effect is mediated by upregulation of
HIF and VEGF, a pathway that may also be relevant in the context of the inflammatory response
to TBI [22, 6].
In focal cortical impact studies increased HIF, VEGF, and VEGF receptor expression is observed in
astrocytes within the contusion and perilesional tissue, as well as amongst infiltrating neutrophils
and macrophages, and is maximal at around day 4 after injury [36, 155]. In one contusion model
VEGF expression was inversely correlated with expression of SMI-71, a marker of BBB integrity
[155]. Similarly, following cold/freeze injury endothelial and astrocyte expression of VEGF peaks
at day 4, in concert with evidence of BBB disruption measured by extravasation of albumin or
fibronectin, and the degree of oedema can be reduced by VEGF receptor antagonists [120, 128].
However, the efficacy of such direct anti-VEGF strategies in more clinically relevant TBI models
(e.g. controlled cortical impact) has not been studied.
Together, these studies strongly suggest a role for VEGF in the delayed phase of BBB permeability
and vasogenic oedema observed in patients with ischaemic and traumatic brain injury. Increased
VEGF has been shown in the circulation and penumbral brain tissue of stroke patients [156], and
microdialysis studies have demonstrated significantly raised intracerebral VEGF concentration
in patients following diffuse TBI and SAH [115, 69]. Crucially, microdialysate levels exceed those
of paired serum samples implying central production as opposed to passive influx from the cir-
culation [69]. However, the relationship between VEGF expression and BBB permeability and
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oedema, as well as the potential of anti-VEGF therapy, has yet to be determined.
It is important to recognise that in addition to potential deleterious actions, VEGF also has a neu-
roprotective role and is important in reparative angiogenesis following injury [191]. Upregulation
of VEGF prior to transient ischaemia has a preconditioning effect and reduces final infarct volume
[151]. However, when administrating exogenous VEGF as a neuroprotective strategy following a
lesion, timing is critical: intravenous recombinant VEGF within one hour of transient ischaemia
significantly exacerbates vasogenic oedema, whereas at 48 hours the same dose enhances angio-
genesis in the ischaemic penumbra and significantly reduces final infarct volume [205].
1.4.3 Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) are a family of over 20 extracellular endopeptidases that cleave
a wide range of protein substrates in diverse signalling pathways [121]. In particular, the subfam-
ily of gelatinases, MMP-2 (Gelatinase A) and MMP-9 (Gelatinase B), have been implicated as key
mediators of proteolytic blood brain barrier (BBB) disruption associated with traumatic injury,
ischaemia, and neuroinflammatory disorders [4, 9, 64].
In the rat cortical contusion model MMP-9 expression was increased in lesioned tissue compared
with contralateral uninjured brain, and was associated with local BBB permeability and oedema
[153]. Correspondingly, an MMP inhibitor (GM6001) reduced the degree of BBB leakage and
the extent of oedema. In a similar mouse model, MMP-9 knockout animals were found to have
smaller final lesion volume and better functional recovery compared to wildtype mice [64].
Tissue samples from patients requiring surgical resection of brain contusions have been shown
to have significantly higher expression of MMP-9 compared with lobectomies performed for non-
trauma indications [186]. Furthermore, in vivo microdialysis studies in TBI patients have also
shown increased interstitial concentrations of MMP-9 and possibly MMP-2 early following injury,
although it is unclear if this is a localised response to brain parenchymal injury, a reflection of a
diffuse brain injury process, or potentially a consequence of a systemic inflammatory response to
trauma [187, 138].
Mechanistically, MMPs have been shown to directly disrupt tight junctions (TJ) between endothe-
lial cells through cleavage of the extracellular domains of critical structural proteins including
claudin and occludin [202, 29]. This process dramatically alters the water reflectance and so-
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lute permeability of the BBB, exacerbating vasogenic oedema, and also contributing to immune
cell invasion into the CNS. These molecular events provide a framework for the microvascu-
lar failure which is thought to underlie contusion expansion [96]. Multiple upstream signalling
molecules have been shown to have a role in regulating the expression and activation of MMP-9,
including cytokines (e.g. IL-1b), growth factors (e.g. TGFb, VEGF), neurotransmitters and small
molecules (e.g. histamine, nitric oxide), and hormones (e.g. epinephrine) [181]. In the wider ex-
perimental brain injury literature, MMPs have been identified as mediators of lesion expansion
and perilesional oedema in models of ischaemic stroke and intracerebral haemorrhage [141, 84].
Importantly, recent evidence has highlighted the crucial roles that MMPs have in the subacute
and chronic reparative processes following brain injury, such as neurovascular remodelling and
migration of cells from the subventricular zone to damaged tissue [206, 140].
Grosslete et al. and Zheng at el. have previously reported elevated levels of MMP-9 in CSF sam-
pled acutely from TBI patients via ventriculostomy, with comparable temporal profiles demon-
strating greatest concentrations in the first sample at 24 hours post-injury followed by a decline,
but remaining higher than control CSF for at least 72 hours [206, 140]. Vilalta et al. studied four
patients with diffuse brain injury using microdialysis and found similar early elevation of cerebral
MMP-9 concentrations [187]. More recently, Roberts et al. conducted a single site microdialysis
study of MMP-1, -2, -3, -7, -8, and -9 in eight TBI patients with a mixture of diffuse and focal
injuries; similarly to the present study, they found MMP-9 was increased early following injury
and thereafter declined [138].
1.4.4 Nitric Oxide
Nitric Oxide (NO) is a highly diffusable radical gas molecule that is synthesised from the amino
acid L-arginine by the nitric oxide synthase (NOS) family of enzymes [57]. NO has a variety
of roles in neurotransmission and synaptic modulation, intracellular signalling, neuroinflamma-
tory cascades, and in the regulation of cerebrovascular tone and cerebral blood flow [57, 34].
Three NOS isoforms have been identified in humans: endothelial NOS (eNOS), neuronal NOS
(nNOS), and inducible NOS (iNOS). Both eNOS and nNOS are constitutively expressed in the
brain whereas iNOS is upregulated in response to injury [175, 57].
Broadly, cerebral autoregulation comprises mechanoregulation (maintenance of constant flow
with varying systemic arterial blood pressure) and chemoregulation (maintenance of flow in re-
sponse to changing CO2 concentrations due to metabolic pertubations and during hypoxia) [57].
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NO is a key mediator of both CO2 chemoregulatory pathways [102] and is necessary for augment-
ing blood flow in response to hypoxia [166]. In the context of TBI this would suggest a beneficial
role for NO in maintaining constant CBF under the stress conditions following injury, and that
relative NO depletion may be a factor in post-injury ischaemia and loss of flow-metabolism cou-
pling [57].
However, excess NO may be a factor in post-traumatic dysautoregulation, vasoplegia and va-
sodilatation, and hyperaemia, with consequent raised intracranial pressure, and has also been
identified as a component of the pathway resulting in blood-brain barrier breakdown by VEGF
[52, 34, 147, 188]. Furthermore, following cerebral insults, it has been shown that eNOS can be-
come uncoupled from its cofactor tetrahydrobiopterin, resulting in the alternative production of
superoxide, a radical that is neurotoxic. Superoxide may in turn react with NO to form peroxyni-
trite that is also neurotoxic and depletes available NO.
NO itself is difficult to assay in clinical samples owing to its short half life. However, assay-
ing concentrations of stable NO metabolites nitrite and nitrate (NO2 and NO3, collectively NOx)
is a validated method of indirectly quanitfying endogenous NO synthesis [137]. In humans, NOx
have been assayed in CSF and microdialysate of diffuse-injury pattern TBI patients. A series of
eleven TBI patients who underwent regular CSF sampling suggested a peak in NOx at approx-
imately 24h following injury [178]. The concentration of NO was correlated with that of IL-8,
suggesting that NO levels may reflect the degree of post-TBI inflammatory burden [178]. In a
pilot study of twelve brain injury patients (11 TBI), studied with microdialysis, extracellular NOx
concentration was found to be correlated with higher cerebral glucose and lower lactate/pyruvate
ratio, suggesting a beneficial metabolic effect of higher NO concentrations [24]. However, a more
recent microdialysis study in eleven TBI patients found significantly higher NO concentrations
within the first 48h from injury amongst patients who died compared with survivors, suggesting
that NO is a either a marker of more severe primary insult or that it potentially contributes to
secondary injury and likelihood of poor outcome [174].
1.5 Metabolic Dysfunction Following Traumatic Brain Injury
Metabolic dysfunction has been described in acute brain injury of various aetiology, including
TBI, ischaemic stroke, and intracerebral haemorrhage, and has an important role in secondary
injury cascades such as the induction of pro-inflammatory cytokine signalling and microvascular
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breakdown causing blood brain barrier permeability [111, 167]. Metabolic crisis in astrocytes and
neurons will potentiate the activation of IL-1b and VEGF axes and their downstream effectors of
BBB opening. Metabolic crisis induced within endothelial cells has been shown to directly result
in increased permeability [45].
Manipulation of systemic and, directly or indirectly, cerebral energy metabolism may therefore
be a potential therapeutic avenue to limit or reduce BBB opening and vasogenic oedema in TBI
patients. However, this requires a suitable classification of the differing states of metabolic de-
rangement so that appropriate interventions are applied with the aim of correcting or normal-
ising cerebral metabolism. Various categories of cerebral metabolic dysfunction have been hy-
pothesised and demonstrated in evidence accrued from cell culture and tissue models, and in
animal and human studies. Broadly, these can be organised under three terms: cellular substrate
deficiency (as a consequence of tissue ischaemia or local diffusion barriers), aerobic glycolysis,
or, lastly, a failure of oxidative phosphorylation that has been dubbed ’mitochondrial dysfunc-
tion’ [27]. Distinguishing these dynamic states within individual TBI patients in vivo over time
is important as potentially simple interventions, such as improving cerebral perfusion and sup-
plementing systemic glucose or oxygenation, may be sufficient to overcome local deficiency or
provide hyperglycolitic tissue with sufficient substrate. In contrast, mitochondrial dysfunction
would not be expected to respond to these manoeuvres and experimental alternatives such as
direct succinate supplementation into the Krebs cycle may may be appropriate [171, 164].
Cerebral microdialysis is an invasive neuromonitoring technique that permits continuous real-
time sampling of brain extracellular fluid and assessment of cerebral metabolism in the intensive
care unit [79]. Standard metabolites assayed on bedside analyzers include glucose, lactate, pyru-
vate and glutamate, which permit characterisation of glycolysis and oxidative phosphorylation
(Fig 1.5). There is a body of observational evidence to support absolute values, ratios, and tem-
poral trends of specific metabolites as indicators of cerebral metabolic dysfunction. The most
extensively studied parameter is the lactate/pyruvate ratio (LPR), generally accepted to be an in-
dex of cellular redox state and the balance between oxidative and anaerobic metabolism.
Patients with average or prolonged LPR above thresholds of 25 or 40 are more likely to die or
have unfavourable outcome following TBI [79]. Low cerebral glucose has similarly been asso-
ciated with worse outcome both in observational series and interventional studies comparing
alternative glycaemic control regimens [172]. Identically LPR values can potentially result from
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an infinite range of combinations of absolute lactate and pyruvate concentrations wherein one
or both may be higher or lower than their respective normal range. Similar increases in LPR re-
sulting from very different changes in lactate and/or pyruvate will likely reflect distinct states of
energy compromise, for instance ischaemia or subtrate deficiency as opposed to aerobic hyper-
glycolysis. Thus, there as been much recent work on defining classifications of lactate, pyruvate,
and LPR values that are proposed to map to various metabolic states [144]. A further aspect
crucial to interpreting glucose, pyruvate, and lactate concentrations, and their trends in vivo,
is that they are not independent variables and display strong covariance and autocorrelation,
a fact that is often overlooked or not explicitly addressed in the microdialysis literature [123].
Characterising the functional form (i.e. linear or non-linear) of the relationships between these
metabolites is fundamental to understanding how they change in concert and in forecasting the
response to therapeutic interventions. Moreover, characterising the typical metabolic derange-
ments localised to pericontusional brain is key to designing treatment that attempts to support or
normalise metabolism in these brain regions to limit the development of vasogenic oedema and
further ischaemia.
Figure 1.5: Schematic of the major metabolic pathways in the brain. Glucose is converted through glycolysis to pyruvate,
which then enters the tricarboxylic acid (TCA) or Krebs’ cycle in mitochondria after forming acetyl-CoA. Alter-
natively pyruvate may be converted to lactate. The pentose phosphate pathway is an alternative source of
reducing agents. Reproduced under Creative Commons attribution licence from [25]
1.6 Summary and Objectives
In vitro and pre-clinical studies have suggested a number of pathophysiological processes are ini-
tiated following brain injury that can ultimately contribute to increased permeability of the BBB,
progression of vasogenic oedema, and lesion expansion. Identifying which of these are salient
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in patients with contusional TBI is an important goal to refine the development and targeting of
therapies to limit contusion progression.
The principal objectives of this work are threefold: firstly, to establish a robust methodology to
assess the temporal course of contusion progression in TBI patients; secondly, to interrogate the
localised response of key mediators of BBB permeability directly in the pericontusional brain of
TBI patients; and thirdly, to characterise the cerebral metabolic dynamics in brain injury patients.
1.7 Hypotheses
• Study I: Measuring Contusion Volume
– H1: Stereology is an accurate method for measuring volume of brain lesions of variable
morphology
– H2: Contusion volume expansion predominantly occurs in the first 72h following in-
jury.
• Study II: Quantifying Blood Brain Barrier Permeability
– H3: Dynamic contrast enhanced computed tomography can quantify the severity of
BBB permeability in the vicinity of brain contusions.
– H4: Maximal BBB permeability is observed at around 72h following injury.
• Study III: Peri-contusional Inflammation
– H5: Pericontusional brain exhibits a pro-inflammatory signature following TBI.
– H6: Vascular Endothelial Growth Factor exhibits higher expression in pericontusional
brain following TBI.
• Study IV: Matrix Metalloproteinases in Peri-contusional Brain
– H7: MMP-9 shows increased expression early following TBI and is primarily localised
to pericontusional brain.
– H8: MMP-2 shows delayed increase in expression following TBI that is also primarily
localised to pericontusional brain.
• Study V: Nitric Oxide in Peri-Contusional Brain
– H9: NO concentrations are higher in pericontusional brain following TBI.
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– H10: NO is correlated with energy metabolites in both pericontusional and radiologi-
cally normal brain.
• Study VI: Cerebral Metabolism following TBI
– H11: Cerebral metabolic parameters predict neurological outcome following TBI
– H12: Derangements in LPR and cerebral glucose are different in radiologically normal
and contused brain following TBI.
– H13: There are defined functional relationships between the principal energy molecules
assayed with microdialysis, namely glucose, pyruvate, and lactate.
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Chapter 2
Generic Methods
2.1 Microdialysis
Microdialysis is a technique that is unique in allowing in vivo sampling of interstitial fluid from
any accessible tissue or organ. All components of the microdialysis system used in this research
are approved for clinical application.
2.1.1 Microdialysis Catheter
The microdialysis catheter consists of a concentric dual lumen tube of 0.5mm outer diameter. The
terminal 10mm of the outer tube is formed by a semipermeable membrane. Fluid (perfusate) is
continuously pumped by a microinfusion syringe-driver pump via the inflow catheter into the
outer tube towards the catheter tip. The returning fluid (dialysate or microdialysate) passes via the
inner tube and outflow catheter to be collected in a vial that is changed at regular intervals (Fig
2.1).
The semipermeable membrane of the catheter rests in the brain parenchyma and molecules dif-
fuse from the intersistium/extracellular fluid into the perfusate and can then be assayed in the
dialysate. From the perspective of examining the role of intercellular messengers such as cy-
tokines and matrix metalloproteinases, the extracellular space is compartment in which these
mediators are secreted, are at highest concentration, and where they act on their cognate recep-
tors or substrates.
21
CHAPTER 2. GENERIC METHODS
The size of the pores in the semipermeable membrane determine a nominal molecular weight
cut-off (MWCO) for the catheter. For clinical applications the available catheters generally ei-
ther have either a MWCO in the region of 20kDa or 100kDa. For assaying small molecules (e.g.
glucose) either MWCO is acceptable but high MWCO catheters (i.e. 100kDa) are required to ef-
fectively recover larger molecules, including proteins.
For the retrospective studies presented here the earlier patients received 20kDa CMA70 catheters
but more recently 100kDa CMA71 catheters have been routinely inserted. For all studies of cy-
tokines and MMPs the CMA71 100kDa MWCO catheters were used.
Figure 2.1: Schematic representation of the microdialysis apparatus: (1) Battery powered micropump, (2) Microdialysis
catheter implanted in tissue. The catheter consists of concentric outer (2a) and inner (2b) tubes and semiper-
meable membrane extending 10mm at the distal end (2c). The golden tip (2d) on each catheter facilitates
visualisation on CT. (3) Microvial holder, with needle that on insertion of the vial penetrates its lid. (4) Mi-
crovial for collection of dialysate. Reproduced from [62]
2.1.2 Relative Recovery
The ratio of the concentration of a diffusible substance recovered in the microdialysate compared
with its true external concentration is termed the relative recovery (RR). Several factors influence
the RR, including catheter material and porosity (i.e. the MWCO), the molecular weight and
ionic charge of the molecule of interest, and flow rate of the perfusate. Generally, the RR of any
given substance is improved with lower flow rates, at the expense of recovering lower volumes
of dialysate and reducing the temporal resolution of the technique. The RR of any molecule of
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interest can be measured in vitro but this may not necessarily accurately reflect the in vivo RR. It is
not usually possible to directly assess RR in vivo but it can be estimated by measuring concentra-
tions recovered at two or more flow rates and extrapolating to the ’zero-flow’ intercept.
2.1.3 Perfusate
The standard perfusion fluid for clinical microdialysis is an isotonic aqueous solution with similar
electrolyte composition to the brain extracellular space (ECF): NaCl 147mM, KCl 2.7mM, CaCl2
1.2mM, and MgCl2 0.85mM. To improve the RR of larger molecules, specifically proteins, the per-
fusate can be supplemented with a macromolecule such as dextran or albumin. Previous studies
in our group have shown that standard perfusate solution with the addition of 3.5% Human Albu-
min Solution (HAS) improves the in vitro recovery of a range of cytokines. This ’colloid’ perufsate
is manufactured and tested at the Ipswich Hospital Manufacturing Pharmacy Unit, Ipswich, UK.
All studies examining the concentration of proteins used the 3.4% HAS supplemented perfusion
fluid. Irrespective of the type of perfusate all studies were conducted at a constant flow rate of 0.3
microL/min
2.1.4 Microdialysate collection and bedside analysis
In routine clinical application the collection vials are changed at hourly intervals and then placed
immediately on a bedside CMA600 or Iscus analyser to quantify the concentrations of glucose,
pyruvate, lactate, glutamate, and glycerol. Reference values for these analytes in normal brain
have been reported [136] and are shown in Table 2.1. An assay for urea is also available but
not used in our centre. The bedside analyzers both employ a standard voltametric assay. The
timecourse data of the analytes are displayed for the clinical team to use as a guide to clinical
management. For the protein studies the remaining microdialysate following the bedside analysis
was collected and stored as soon as possible at -80◦C for later analysis. In vitro studies indicate
that cytokines are relatively stable in microdialysate solution at body and room temperature for
several hours [68].
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Analyte Concentration in Normal Brain
Glucose (mmol/L) 1.7 +/- 0.9
Pyruvate (micromol/L) 166 +/- 47
Lactate (mmol/L) 2.9 +/- 0.9
Lactate:Pyruvate Ratio (LPR) 23 +/- 4
Glycerol (micromol/L) 35 +/- 11
Glutamate (micromol/L) 16 +/- 16
Table 2.1: Reference values for standard clinical microdialysis analytes assayed in normal brain [136]
2.2 Additional Monitoring
2.2.1 Intracranial Pressure Monitoring
All patients in the included studies had intracranial pressure continuously monitored using a in-
traparenchymal strain gauge sensor (Codman, Raynham, MA, USA). Prior to insertion the sensor
is zeroed to atmospheric pressure in sterile saline and then inserted to a depth of 2-3cm into the
brain white matter. The ICP waveform is continuously displayed at the bedside.
2.2.2 Brain Tissue Oxygen Tension
Brain tissue oxygen (PbtO2) was measured up to the year 2007 using the Neurotrend probe (Cod-
man, Raynham, MA, USA) which utilises an optical technique to quantify tissue oxygen tension.
Since then all PbtO2) monitoring has been performed using the Licox probe (Integra LifeSciences,
Plainsboro, NJ, USA). This is provided pre-calibrated with a unqiue reference card that is inserted
into the bedside monitor.
2.2.3 Arterial Blood Pressure
All patients managed according to the ICP/CPP protocol require continuous invasive arterial
blood pressure monitoring using standard intra-arterial catheters placed typically in the radial
or brachial artery. The ABP monitor was zeroed at the level of the right atrium until 2014, and
thereafter the clinical protocol changed to zeroing at the level of the tragus.
2.2.4 Data Recording
Continuous arterial blood pressure (ABP), ICP, and PbtO2), together with other signals from the
ventilator (e.g. end-tidal CO2) are digitised at 50-240Hz and recorded using ICM+ software on a
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dedicated PC at the bedside.
2.3 Insertion of Intracranial Monitors
Adult patients admitted to the Neurosciences Critical Care Unit (NCCU) at Addenbrooke’s Hos-
pital with Traumatic Brain Injury (TBI) requiring invasive intracranial monitoring for clinical care
were eligible for recruitment to the studies. As part of the standard ICP/CPP targeted care pro-
tocol (1.1), all patients received a triple-lumen cranial access device (’bolt’, Techicam, Newton
Abbott, UK) either placed at the bedside or in theatre. This is a magnetic resonance imaging
(MRI)-compatible device that is secured to the skull and incorporates three equidistant obliquely-
angled ports that permits sterile insertion of compatible monitors. A variety of attachments are
provided to accommodate different monitors and it facilitates easy verification or replacement of
monitors without necessitating further surgery (Fig 2.2).
The standard battery of monitors placed via the bolt includes an intraparenchymal intracranial
pressure transducer (Codman), a Licox tissue oxygen probe, and a CMA71100kDa MWCO gold-
tipped microdialysis catheter (CMA Microdialysis). As these monitors are placed for clinical man-
agement they would normally be inserted by the emergency neurosurgical team. For all patients
recruited to the two-site paired microdialysis study the additional monitors were placed by me.
By default the cranial access device is inserted in the right frontal region, anterior to the coro-
nal suture, as this is the least eloquent region of brain. A left frontal position is suitable if there
are scalp wounds, fractures or other reasons that the right frontal region is not preferred. The skin
is prepared by clipping hair as required and then sterilising with liberal application of povidone-
alcohol or chlorhexidine-alcohol solutions. A 1-2cm linear incision is made and the periosteum
elevated and swept away to reveal the outer bone cortex. Using a custom drill bit with safety
guide, a burrhole is drilled with a manual brace taking care not to suddenly breach the inner
table of the skull and damage the underlying dura and brain. The dura is opened in a cruciate
manner and the pial surface coagulated. The bone channel is then reamed to create a screw thread
which allows the access device to be secured in place. Each of the three channels is confirmed to
be patent without resistance at the cortical surface to deflect the pliable catheters and then the
monitors are inserted in turn. The skin around the access device is approximated with 3-0 nylon
sutures. Once monitoring is completed the monitors and access device are removed at the bed-
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side and the scalp closed with 3-0 silk or nylon.
For patients who require craniotomy or craniectomy to evacuate mass lesions or achieve decom-
pression, monitors can be inserted at the time of surgery by tunnelling through the scalp at the
edge of the craniotomy, insertion into the brain under direct vision, and then secured to the scalp
with 3-0 silk. ICP sensors and microdialysis catheters are suitable to be inserted by this method
but the Licox probe is difficult to secure satisfactorily. The advantage of tunnelled catheters is the
ability to precisely locate the monitor in visibly injured or perilesional brain; the disadvantage is
the inability to change or replace the catheter if it fails or is inadvertently removed without further
surgery.
Figure 2.2: The cranial access device (CAD) with associated monitors place in the three available lumen: microdialysis
(MD), intracranial pressure transducer (ICP), and brain tissue oxygen probe (O2). The CAD is threaded to
allow it to be secured to the burrhole fashioned in the skull. Reproduced from [149] under Creative Commons
attribution licence
2.4 Ethical Approval and Procedures
The two-site microdialysis studies reported here were conducted following ethical approval for
the insertion of additional monitoring (for up to ten days following injury) and performing the
dynamic contrast enhanced computed tomography (DCE-CT) imaging. This research protocol
was approved by the East of England NHS Research Ethics Committee, reference 11/EE/0075.
Acutely, relatives were approached for written assent to enrol a patient in the research prior to
any procedures being performed. If patients subsequently recovered sufficiently and regained
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competence, the research was again discussed directly with them to seek affirmation of consent;
if refused the patient would be withdrawn from the study.
For larger cohort study, microdialysis catheters were inserted and samples collected as part of
routine care. Retention of this data for research purposes was approved by the Cambridgeshire
Local Research Ethics Committee as part of an ongoing ‘Blood flow, swelling and metabolism
after head injury’ project (Protocol 30).
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Chapter 3
Study I - Measuring Contusion and
Oedema Progression
3.1 Introduction
Haemorrhagic expansion and progression of perilesional oedema are the critical features of intrac-
erebral haematomas and traumatic brain contusions that can result in tissue destruction, raised
intracranial pressure and cerebral hypoperfusion, herniation, and ultimately death or more severe
disability [135]. Therefore, a method that provides accurate and efficient estimation of the volume
of intracerebral haematoma or contusions and perilesional oedema is an essential tool for studies
examining the pathophysiology of these lesions and those assessing the efficacy of therapeutic
interventions.
In the context of stroke, intracerebral haemorrhage (ICH) accounts for 10-15% of all presenta-
tions and haematoma volume is amongst the main prognostic factors that influence outcome and
clinical decision-making [23]. Probably the most widely used estimator of ICH volume in both
clinical practice and research studies is the ABC/2 formula [23, 94]. This is an approximation to
the volume of an ellipsoid where A and B are the maximal orthogonal dimensions (length and
width) measured on the axial imaging slice displaying the largest area of ICH, and C is the prod-
uct of the number of slices on which the ICH appears and the slice thickness (i.e. ’height’ or
maximal rostro-caudal dimension). Studies in TBI have also adopted this heuristic methodology
for estimating the volume of contusions and surrounding hypodensity or oedema.
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Alternative techniques include planimetry, wherein the the lesion is manually outlined on each
image slice and the total volume calculated by the sum of the respective areas multiplied by slice
thickness [80]. However, this is a time consuming process and, particularly when the margins of
the lesion are diffuse or poorly defined (e.g. oedema), the interobserver variation may be sub-
stantial given the potentially infinite degrees of freedom inherent in the approach.
Automated and semi-automated segmentation techniques for radiological images is a well devel-
oped field, and delineation of brain lesions specifically has received much attention. Algorithms
including region growing, watershed transform, and active contour level sets have been reported
to be effective at isolating a variety of lesions, including primary and secondary tumours, stroke,
and inflammatory plaques. However, these algorithms each have a number of parameters that
need to be tuned precisely to the specific characteristics of the lesions of interest before any sat-
isfactory results are obtained. Often the efficacy of the algorithm is very sensitive to a subset of
these parameters and those that are refined on a given training set may perform poorly on what
may appear to be a very similar test-set of scans.
A number of studies have shown that ABC/2 substantially overestimates volume of ICHs classi-
fied as irregular based on qualitative criteria [80, 207, 44]. This can be partially compensated by
increasing the divisor to 3 (i.e. ABC/3) or by adopting the formula 2LC/3 where L is the largest
surface area of ICH on any slice, and C is again height [207, 208]. However, particularly in the
context of traumatic contusions which are often highly irregular, any of the methods that approx-
imates to the volume of a regular solid will be less accurate than a technique which is agnostic to
lesion shape.
Stereology is an established generic technique, developed primarily in microscopy, for estimating
object volume from planar sections and involves estimating the cross sectional areas on parallel
sections by counting the points that fall within the region fo interest using a regular counting grid
- the so-called Cavalieri estimator [119]. Stereology can also be adapted to estimate the surface
area of objects. As there are no underlying assumptions about shape or regularity, stereology
should have predictable accuracy irrespective of lesion morphology. A small number of studies
have reported applying stereology for quantification of anatomical structures on cross sectional
imaging, including a study of five patients with brain contusions, with findings of good accuracy
[85, 48].
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The objectives of this study were, firstly, to quantitatively establish the relationship between mor-
phology and the accuracy of cerebral haematoma volume determined using ABC/2, ABC/3 and
2LC/3 estimators. Secondly, we have assessed the comparative accuracy of estimating volume
with a simple stereological grid technique. Lastly, the stereological approach has been applied
to a cohort of patients with contusional TBI to characterise the temporal evolution of contusion
volume.
3.2 Methods
3.2.1 Design
The first component of this study was performed using fifty standard axial non-contrast com-
puted tomography scans demonstrating a discrete (spontaneous) intracerebral haemorrhage of
variable size and morphology. Scans with ICH extending to the ventricles or subdural space were
excluded. To objectively compare the accuracy of the formula estimators and a stereological ap-
proach an automated procedure was developed to apply both techniques without introducing
user bias or error.
The second component of this study was performed on the set of clinical CT scans of fifty two
patients with contusional TBI. The series of scans for each patient obtained within 14 days of in-
jury were analysed using the stereological technique to estimate contusion and oedema volume.
3.2.2 Image processing
All image processing was performed using the SimpleITK (www.simpleitk.org) interface to the
Insight Toolkit (ITK, www.itk.org). ITK is a free and mature open source library of image pro-
cessing, registration, and segmentation component routines that can be composed in to a flexible
analysis pipeline. SimpleITK is a layer over ITK that provides a simplified procedural interface to
the majority of ITK functions and also has an R-language wrapper that allows rapid prototyping
and interactive image analysis within the full R language environment.
Anonymised non-contrast 4-6mm slice thickness axial computed tomography scans DICOM files
were imported and any gantry tilt corrected with a affine shear transform calculated from the
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origins of the first two image slices - the DICOM header information regarding gantry tilt was
found to be often absent or inaccurate when compared with calculated values from image coor-
dinates. Ground truth segmentation of the ICHs was performed by first cropping the volume to a
margin no less than 5mm around the haematoma in all planes. The image slices were then thresh-
olded to a range of Hounsfield units representing acute blood, i.e. 45-100. The resulting binary
mask of the haematoma was used as the reference and both volume and surface area were calcu-
lated. Regularity of each haematoma was quantified by calculating its sphericity S, according to
S = pi1/3(6V)2/3/T, with V the volume and T the surface area. Sphericity has values ranging be-
tween 0 and 1; a perfect sphere has S = 1 and this declines toward 0 as an object’s shape becomes
progressively more eccentric/non-spherical or irregular.
3.2.3 Volume Estimation by ABC/2, ABC/3, and 2SH/3
To objectively apply the three formula techniques as a clinician would, the area of the binary
haematoma mask on each imaging slice was computed and the largest selected. On the selected
slice the largest dimension of the haematoma (Feret diameter) was obtained and then the maxi-
mal orthogonal dimension calculated. The number of slices on which the haematoma mask was
present was counted and thus all the required variables for the formula calculations were ob-
tained.
3.2.4 Stereological Volume Estimation
Binary images of the same dimensions as the respective scan consisting of regular grids of voxels
with point-spacing of 5, 10, or 20mm (equivalent to point area of 25, 100, and 400mm2) with
a random horizontal and vertical offset were generated for each haematoma. With a series of
binary logical operations the grid points falling within the haematoma mask were segmented and
then automatically counted. Haematoma volume estimates were then obtained by multiplying
the total number of points within the ICH by the point-area (PA) and slice thickness. For each
haematoma and at each point-spacing the process was repeated at ten random grid offsets (Fig
3.1).
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Figure 3.1: Segmentation and Stereological Procedure. A: An example of an ICH included in the study. B: Segmentation
by thresholding (red line). C: Crosshair stereology grid with point-area of 100mm2 (blue); crosses falling within
the ICH were automatically counted, in this case n=11.
3.2.5 Contusion Stereology
To apply stereology volume estimation to scans from TBI patients, anonymised standard non-
contrast soft tissue kernel CT images with 1-5mm slice thickness were imported and corrected
for gantry tilt. The volumes were then resampled to 1mm isotropic voxel spacing with linear
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interpolation and windowed to 1-100 Hounsfield Units. A contrasting three-dimensional grid of
voxels with 10mm point spacing in three dimensions (i.e. a point volume of 1000mm3, equivalent
to 1cm3 or 1ml) and with a random offset in each plane was then applied to the CT images. The
slices on which the grid appeared were extracted from the full volume and saved; this subset of
the isotropic volume was then reviewed and the grid points within regions of haemorrhagic con-
tusion and pericontusional oedema were counted manually.
3.2.6 Statistical Analysis
Accuracy of volume estimation was quantified as the mean difference between estimated and
reference volumes with 95% limits of agreement (LoA: Mean +/- 1.96SD) and visualised as a
Bland-Altman plot. Correlation was measured with Pearson’s r. Data are reported as mean (SEM)
unless otherwise stated. The temporal course of contusion volume was characterised by fitting
generalised additive models (GAM) separately for the haemorrhagic and oedema components,
and the total lesion volume. Standard 10-knot cubic spline bases were used and a random effect
(intercept) included for each patient to account for the variable initial contusion volumes. GAMs
were fitted using the mgcv R package.
3.3 Results
3.3.1 ICH Characteristics and Reference Volumes
Fifty CT scans of patients presenting with acute ICH were selected, with slice thickness of 4-
6mm. ICH reference volumes obtained by threshold segmentation ranged from 1.1 to 142.2cm3
with mean 34.4 (5.3) cm3. ICH sphericity ranged from 0.27 to 0.58, with mean 0.42 (SEM 0.01).
ICH volume and sphericity were inversely correlated (r=-0.58, p<0.001; Fig 3.2).
3.3.2 ICH Volume Estimation by ABC/2. ABC/3, and 2LC/3
Difference plots (Fig 3.3) showed ABC/2 estimates exceeded the reference volume for all but two
of the ICHs and there were progressively larger errors in in the ABC/2 estimates as ICH volume
increased, correspondingly with wide LoA. Estimates of volume using ABC/3 and 2LC/3 were
more accurate. However, estimates with all three formulae showed an inverse correlation with
sphericity (Fig 3.4 ABC/2: r=-0.57, p<0.001; ABC/3: r=-0.33, p<0.05; 2LC/3: r=-0.49, p<0.001).
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Figure 3.2: Scatter plot of sphericity and reference haematoma volume (cc=cm3); Horizontal axis is shown on a square
root scale for clarity
Figure 3.3: Accuracy of Formula-Based Volume Estimates. Difference plots of error vs. reference volume (cc=cm3). Error
of A: ABC/2 estimates, B: ABC/3 estimates, C: 2LC/3 estimates. Axes are plotted on square root scales for
clarity. Blue/solid line indicates mean error; green/dotted lines indicate 95%LoA.
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Figure 3.4: Relationship between the error of the formula-based estimates and the haematoma sphericity. Error of A:
ABC/2 estimates, B: ABC/3 estimates, C: 2LC/3 estimates. Axes are plotted on square root scales for clarity.
3.3.3 Stereological Volume Estimation
Difference plots of the stereological volume estimates are shown in Fig 3.5. LoA widened with
increasing PA but all were narrower than those for ABC/2, ABC/3, or 2LC/3. There were no
correlations between stereology estimates and sphericity (all r<0.05, p>0.1).
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Figure 3.5: Accuracy of Stereology Volume Estimates. Difference plots of error vs. reference volume (cc=cm3). Error of
stereology with A: PA=25mm2, B: PA=100mm2, C: PA=400mm2. Axes are plotted on square root scales for
clarity. Blue/solid line indicates mean error; green/dotted lines indicate 95%LoA.
3.3.4 Contusion Volume Measurement and Temporal Progression
The stereological technique was applied to the non-contrast routine clinical CT head scans of 52
TBI patients with predominantly contusional TBI (Table 3.1). Patients with a high-velocity diffuse
injury pattern or primarily extra-axial haematomas were excluded. All patients required inten-
sive care management of their traumatic brain injury; the median best pre-inubation GCS was 8.
All patients were monitored with a standard clinical triple lumen cranial access device,
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A total of 252 scans were analysed; each patient had between two and nine suitable scans within
14 days of injury with median number of five.
On the presenting CT scans mean haemorrhagic contusion volume was 20.2ml (SEM 2.7ml, range
1-86ml), and the mean initial oedema volume was 18.0ml (SEM 3.2ml, range 0-112ml; Fig 3.6).
Generalised additive mixed models with 10-knot cubic splines and per-patient random effects
were generated to model the temporal course of haemorrhagic contusion volume, oedema vol-
ume, and combined total lesion volume (Fig 3.8). This showed that contusion progression was
most rapid within the first 72h following injury. Expansion of the haemorrhagic core reached its
maximum at around 4 days from injury, whereas pericontusional oedema continued to accumu-
late at a slower rate until approximately ten days from injury, and thereafter plateaued or slowly
declined.
Characteristic Total N = 52
Age (median [IQR] years)
48 [31-62]
Sex (N [%])
Male 42 [80.8]
Female 10 [19.2]
GCS (N [%])
3-8 26 [50]
9-12 12 [23]
13-15 12 [23]
N.A. 2 [4]
Pupils (N [%])
Both reactive 42 [80.7]
Unilateral unreactive 5 [9.6]
Bilateral unreactive 0 [0]
N.A. 5 [9.6]
Mechanism of Injury (N [%])
Assault 8 [15.4]
Fall 24 [46.2]
Cyclist 8 [15.4]
Pedestrian RTA 2 [3.8]
Occupant RTA 10 [19.2]
Table 3.1: Admission baseline characteristics of the patient cohort analysed for contusion progression.
IQR, interquartile range; GCS, Glasgow Coma Scale; N.A., not available.
3.3.5 Contusion Progression, Intracranial Pressure, and Metabolism
There was a significant correlation between maximum contusion expansion i.e. the change in total
volume of contusion, incorporating both haemorrhage and oedema, from baseline, and mean ICP
over the period of monitoring (Pearson r=0.49, p=0.0012; Fig 3.9A). There was a similar trend to
association between contusion expansion and mean LPR (Fig 3.9B). Dividing the patient group in
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Figure 3.6: Histograms of the (A) core haemorrhage contusion volume and (B) pericontusional oedema volume on the
first available CT for each patient
to those with mean LPR <25 and >25 showed that patients with metabolic dysfunction (i.e. LPR
>25) also had significantly greater volume expansion of their contusions (76.5 vs 53.4 ml, t=-2.13,
p=0.038; Fig 3.9C)
3.4 Discussion
3.4.1 Validation of the stereology technique
This study provides an objective and quantitative comparison of the accuracy of alternative tech-
niques for estimating brain lesion volumes and demonstrates that stereology is a simple and ef-
fective method that can applied to lesions of any shape or size. This finding accords with intuition
as in the limit of grid point spacing equal to the image resolution stereology, would be identical
to counting the number of voxels within a lesion. At spacings greater than the image resolution
stereology will remain accurate at the expense of a degree of precision and tuning the spacing to
the particular application defines the magnitude of this trade-off.
To assess stereology and commonly used heuristic formulae for estimating lesion volume the
reference or ground-truth volume measurements were obtained by a fixed thresholding opera-
tion, hence discrepancies in estimated volumes represented systematic error associated with the
specific techniques being tested, rather than inter- or intra-observer variation or user bias. The
significant findings are that volume estimates using the ABC/2, ABC/3, and 2LC/3 formulae all
suffer increasing error as lesion volume increases and their regularity decreases. ABC/3 was least
susceptible and provided the most precise estimates. The findings indicate that larger intracere-
bral haematomas have more irregular morphology and therefore the assumption of ellipsoidal
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Figure 3.8: Generalised additive modelling of mean contusion volume, pericontusional oedema volume, and total lesion
volume over the first two weeks following injury, quantified using stereology; n=52 patients. Per-patient random
effect (intercept) included, dashed lines indicate the 95% confidence interval of the mean trend
shape loses its validity.
These data are consistent with earlier reports that ABC/2 overestimates ICH volume, particu-
larly for irregular haematomas, although the magnitude of error observed in the present study
was greater. Previously, ICH shape has only been qualitatively assessed as ’regular’ or ’irregular’
using subjective and study-specific criteria, rather than described by a quantitative metric such
as sphericity. As in prior studies of ABC/3 and 2LC/3 we found them to be more accurate than
ABC/2, but the degree of error remained dependent on ICH morphology [80, 207, 44].
In comparison to the three formulae, stereological estimates had excellent accuracy and narrower
limits of agreement at all grid spacings. Clearly, the relative accuracy of the technique will dimin-
ish for objects or lesions of size close to, and certainly below, the point-area. However, a clinically
relevant spectrum of ICH size was included in this study and the accuracy was maintained within
acceptable limits for all spacings chosen. Depending on the application, grid spacing can be ad-
justed to maintain a suitable balance between precision and the efficiency of point counting. The
point spacing can be reduced to achieve an arbitrary level of precision if required for a particu-
lar study. The superior accuracy of stereology over volume estimates based on approximating
anatomical structures as ellipsoids has previously been shown in other radiology contexts, for
example measuring the volume of the uterus on MR images [85].
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Figure 3.9: Association between contusion progression (i.e. difference between baseline and maximal volume of the total
contusion including haemorrhage and oedema) and intracranial monitoring. (A) contusion expansion and ICP,
(B) contusion expansion and LPR (C) contusion expansion in patients with mean LPR <25 and >25.
41
CHAPTER 3. STUDY I - MEASURING CONTUSION AND OEDEMA PROGRESSION
Importantly, the volume estimates with stereology showed no correlation with sphericity, reflect-
ing that stereology is inherently agnostic of object morphology. For this reason, stereology should
be equivalently accurate for measuring the volume of any lesion, irrespective or morphology, e.g.
extra-axial haematomas, intraventricular haemorrhage, or tumours. Similarly, the volume of mul-
tifocal lesions, such as traumatic brain contusions, could be estimated using a technique such as
ABC/2 on each individual region of haemorrhage, but this would both be a time consuming pro-
cess and prone to similar systematic errors as described in this study. In contrast stereology can
be applied to multifocal lesions with the expectation of comparable accuracy as for the estimation
of volume of solitary objects.
3.4.2 Contusion progression
The existing literature on contusion progression suffers from a lack of consensus in terminology
and methodology, and consequent ambiguity as to the specific phenomenon under investgation.
Various descriptions include ’progressive haemorrhagic injury’, ’delayed intracerebral haemor-
rhage’ and ’haemorrhagic progression of contusion’. Further, studies have tended to examine
only the evolution of the haemorrhagic component of contusions from presenting CT to the next
available scan within 24-72h, rather than the full temporal course as examined in the present
study, and often set arbitrary thresholds, for example 30% relative increase or an absolute increase
by 10ml, which can nullify or inflate changes that are clinically important or silent, respectively
[3]. Lastly, the focus has typically been solely on the volume of haemorrhage without assessing
the co-evolution of pericontusional oedema, which, as this study shows, usually accounts for the
greater proportion of total lesion volume.
In a selection of fifty-two patients with contusional brain injury, stereology was employed to
characterise the temporal course of contusion volume, comprising of both the haemorrhagic core
and pericontusional oedema. The mean non-parametric function fit to the data using a gener-
alised additive mixed model showed that both contusion core and oedema expand principally
over the first 72h following injury. Of note, over this period there an approximately linear in-
crease in oedema volume was observed, thereafter expanding at a slower rate and plateauing at
around ten days following injury. The mean time course for the haemorrhagic core reached its
peak at around day 3-4 and thereafter the hyperdense component of contusions reduced in vol-
ume. This presumably reflects both a proportion of the haematoma breakdown products being
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absorbed and the changing CT attenuation of blood in the subacute phase as it becomes more iso-
dense with brain. Combined, the overall lesion volume exhibited the most rapid increase over the
first 72h following injury, peaking between 5 and 7 days, and then gradually decreasing. These
findings accord with the familiar clinical experience that the majority of patients that develop sig-
nificant cerebral oedema do so over the first several days following admission to intensive care,
with intracranial pressure and compliance subsequently improving towards the end of the first
week.
The observed association between contusion expansion and intracranial pressure is not unex-
pected, as lesion expansion is one of the major contributors to raised ICP in this patient popu-
lation. However, determining the true strength of association between contusion expansion and
ICP is confounded by intensity of treatment directed at ICP control. The finding of more pro-
nounced metabolic dysfunction in this patient group suggests that this may a potential cause
of more aggressive contusion expansion and thus treatment aimed at correcting LPR could at-
tenuate increases in oedema. However, the cause-and-effect relationship here is uncertain and
contusion progression resulting in raised intracranial pressure and impaired cerebral perfusion
may be source of the association.
3.4.3 Limitations
Although the inherent accuracy and precision of the stereology technique can be calculated with
reference to grid size used, the inter-rater reliability of applying this to the specific measurement
of contusions has not been determined and would be the subject of further study. However, a
prior study utilising the stereological technique to determine total intracranial volume showed
the interobserver coefficient of variation was 4.0% [114].
3.5 Summary and Context
This study has validated a simple, robust, and generalisable technique for volume quantification
of intracerebral lesion including haematoma and oedematous brain. Using this method the tem-
poral course of contusion and associated oedema progression was characterised. The majority of
haemorrhagic expansion and increase in pericontusional oedema occurs within 72h from injury
and thereafter plateaus before slowly receding.
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3.5.1 Hypotheses
• H1: Stereology is an accurate method for measuring volume of brain lesions of variable
morphology
Based on the current evidence this hypothesis is accepted.
• H2: Contusion volume expansion predominantly occurs in the first 72h following injury.
Based on the current evidence this hypothesis is accepted.
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Chapter 4
Study II - Dynamic Contrast
Enhanced Computed Tomography
Assessment of Blood Brain Barrier
Permeability
4.1 Introduction
Reliable quantification of blood brain barrier permeability in vivo is an important tool for investi-
gating the pathophysiology of barrier disruption and vasogenic cerebral oedema, and to measure
the effects of therapeutic interventions targeted at preventing or limiting these processes. All ra-
diological techniques for detection of BBB permeability have in common the use of intravascular
(usually administered intravenously) tracer or contrast agent to which the BBB is normally imper-
meable and are thus able to label or highlight regions of abnormal permeability. The molecular
size of the compounds can be varied to assess the severity of barrier disruption; most are small
molecules that are able to diffuse via paracellular routes when there is any degree of tight junc-
tion breakdown between endothelial cells, alternatively contrast agents have been complexed
with molecules of several kiloDaltons (e.g. albumin) such that contrast extravasation indicates
significant BBB opening to proteins and other endogenous macromolecules.
Radioligand-based tracer techniques including SPECT and PET have been validated for quantita-
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tive measurements of BBB permeability, however, semiquantitative techniques based on dynamic
contrast enhanced computed tomography (DCE-CT; iodinated contrast) and magnetic resonance
imaging (gadolinium-based contrast) are cheaper and more widely available and have been in-
troduced into routine clinical practice [182, 28]. Permeability maps from both MRI T1-based dy-
namic contrast enhancement and T2-based dynamic susceptibility imaging have been shown to
be effective at differentiating intrinsic tumour types and also in prediction of haemorrhagic trans-
formation of ischaemic stroke. Similarly, now that whole-head DCE-CT perfusion imaging is
routinely available for acute stroke decision making, permeability maps have been shown to be
independent predictor of stroke progression and haemorrhagic transformation [134, 145].
This study sought to establish whether DCE-CT is able to show localised BBB permeability re-
lated to contusions and/or pericontusional brain in TBI patients, and whether there are consistent
temporal changes in the extent of any permeability visualised.
4.2 Methods
4.2.1 Design
Adult patients (>16 years) admitted with contusional TBI and requiring intubation, sedation, and
invasive neuromonitoring were selected and informed assent was obtained from relatives. Mon-
itoring and intensive care management was otherwise as per standard local clinical protocols. To
assess temporal progression in permeability each patient was enrolled with the intention of being
scanned within 48 hours of injury and then scanned again between 3 and 6 days following injury.
However, if a patient was clinically too unstable to be transferred to the CT scanner the second
scan was not performed unless a scan also required for clinical purposes.
4.2.2 Computed Tomography Imaging
Dynamic contrast enhanced computed tomography imaging was performed on a Siemens So-
matom Definition Flash Dual-Energy Spiral CT scanner. An initial standard non-contrast scan
was performed immediately prior to each perfusion sequence. For the perfusion imaging, thirty
uniformly spaced sequential volume acquisitions with 10cm coverage, centered over the supra-
tentorial compartment, were obtained at 80kV and 200mA over 45 seconds (i.e. every 1.5s) with
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an additional further five volumes obtained at 13.5s intervals. Total scanning time was therefore
113s. The maximum scan time permitted by the scanner was 120s. A 50ml volume of iodinated
contrast (Iodopam 300) was injected in two phases: 5 ml/s for 6s followed by 1ml/s for a further
20s, with a 50ml saline chaser, via a large bore peripheral venous cannula. Radiation exposure for
each perfusion scan was calculated as no more than 7 milliSieverts.
Initial image processing was performed according to manufacturer’s instructions on a Siemens
SyngoCT workstation with the VolumePCT software module. Raw volume data was recon-
structed into 5mm slices with a H20f kernel function. Following application of a 4D denoising
algorithm and automatic segmentation of the intracranial compartment, regions of interest (ROI)
were placed on a reference artery (typically the anterior cerebral artery) and vein (sagittal sinus).
Based on the maximal intensity observed in the reference vessels further automatic Hounsfield
unit thresholding was performed to exclude larger vessels from the parameter maps.
The software provides two algorithms for determining permeability based on Patlak analysis
[30, 129] or a proprietary Siemens model. The Patlak approach assumes a two compartment
model of the intravascular (IV) and extracellular (EC) space with unidirectional permeability of
the contrast agent from the IV to EC space but no backflux [129]. The arterial input function is
defined as the Hounsfield number in the selected arterial ROI over time, denoted a(t). The cor-
responding contrast-time function for a given voxel is denoted r(t). The relationship between
dynamic enhancement observed in the voxel and AIF is
r(t) = P
∫
a(t)dt + V · a(t) (4.1)
where P represents the permeability or rate constant of contrast efflux from intravascular to
the extracellular/interstitial space, and V is the volume of distribution of the contrast in the voxel
or ROI. Dividing by a(t) gives:
r(t)
a(t)
= P
∫
a(t)dt
a(t)
+ V (4.2)
From this equation, the standard Patlak approach is to obtain P and V as the gradient and in-
tercept, respectively, of the line fit to the plot of r(t)a(t) against
∫
a(t)dt
a(t) , which can both be determined
directly from the CT image.
The alternative proprietary manufacturer method involves modelling the voxel contrast enhance-
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ment as:
r(t) = r0 + Fin
t∫
−∞
a(t′ − tin) dt′ − Fout
t∫
−∞
a(t′ − tout) dt′ (4.3)
Where Fin and tin are the rate at which contrast arrives at the voxel/ROI (i.e. the CBF) and
the time at which contrast first appears at the ROI, respectively. Fout and tout are similarly defined
for contrast leaving the ROI; r0 is the baseline Hounsfield unit of the ROI. The algorithm then
iteratively identifies values of these variables that minimise the cost function:
∑
n
(
rm(tn)− rt(tn)
)2 (4.4)
where rm(tn) and rt(tn) are the measured and theoretical profiles of contrast enhancement in
the ROI. In this model permeability is then defined as:
P = Fin − Fout (4.5)
For this study the parameter maps obtained were cerebral blood flow (CBF, ml/100g/min),
cerebral blood volume (CBV, ml/100g), time to start (TTS, seconds), mean transit time (MTT, sec-
onds), and permeability (PMB, ml/100g/min) using both the proprietary and Patlak methods .
4.2.3 Image Analysis
Areas of haemorrhagic contusion were manually segmented on the non-contrast axial CT scan
using Fiji/ImageJ and saved as a binary volume of interest (VOI). The non-contrast CT head was
then registered with a rigid affine transform to a reference template CT head in standardised
Montreal Neuroimaging Institute (MNI) space and resampled to 1mm isotropic voxels using the
SimpleITK imaging toolbox suite in the R programming language. Using the transform obtained
in this registration as a starting input, the MIP image was then registered to MNI space and simi-
larly resampled. This final transform was then applied to the respective parameter maps and VOI
and resampled to 1mm isotropic spacing using nearest-neighbour algorithm to avoid artefacts of
interpolation of ’empty’ voxels.
A series of VOIs were generated for each scan using mathematical morphology operations pro-
vided in SimpleITK functions. The contusion VOI was eroded by spherical structuring elements
with 1mm, 2.5mm, and 5mm radii and then the original VOI was subtracted to give three VOIs
48
4.3. RESULTS
of the periphery of the intracontusional tissue of increasing volume. Similarly, the initial con-
tusion VOI was dilated with the same structuring elements, from which the original VOI was
subtracted, to give three VOIs of increasing volume of the pericontusional/oedematous tissue
(Fig 4.1). Finally, a VOI of the the totality of the non-contusional tissue was also generated. There-
fore there was a total eight VOIs for each scan: Contusion VOI, 2mm, 5mm, and 10mm Contusion
Edge (CE) VOIs, 2mm, 5mm, and 10mm Pericontusional Tissue (PT) VOIs and a Non-Contusional
VOI). Each of these VOI masks was applied in turn to their respective parameter maps and the
mean value of the parameter within each VOI was determined.
The mean parameter value in each VOI was analysed in a linear mixed model analysis with the
VOI as a factor and incorporating nested random effects for patient and scan. Pairwise compar-
isons between VOI were obtained with post-hoc tests corrected for multiple comparisons. All
statistical analysis was performed in R (v 3.4.3)
Figure 4.1: Left: unlabelled image. Right: Volume of Interest (VOI) manually circumscribed around the left temporal
contusion (red). A VOI for the pericontusional oedema was then generated by morphological dilatation of the
original VOI with a 5mm diameter spherical structuring element and the original contusion VOI is subtracted
(green). Similar VOIs were generated using 1mm and 2.5mm radius elements and corresponding eroded
VOIs were generated for the periphery of the contusion.
4.3 Results
4.3.1 Patients
Ten patients (9 males, 1 female) were enrolled to the study and underwent a total of sixteen CT
perfusion scans. All the scans were well tolerated and there were no attributable adverse events
due to the imaging or intravenous contrast. Median age of the participants was 51 years and
median best pre-intubation GCS was 10 (Table 4.1). The timing of the CT perfusion scans for each
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patient is shown in Fig 4.2.
Age Sex Mechanism GCS Pupils Marshall GOS
59 F Fall 13 Reactive 2d 1
31 M Fall 10 Reactive 2d 5
29 M Assault 10 Reactive 2d 6
65 M Fall 11 Reactive 3 6
48 M Assault 8 Reactive 2d 1
66 M Cyclist 14 Reactive 2d 7
48 M Pedestrian 7 Unilateral 3 7
31 M Fall 5 Unilateral 3 6
62 M Fall 9 Reactive 2d 6
55 M Pedestrian 8 Reactive 3 8
Table 4.1: Demographics of patients in the CT permeability study. Marshall Category 2d indicates bilateral contusions, and
Category 3 indicates contusions with basal cistern effacement. GCS: Glasgow Coma Scale, GOS: Glasgow
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Figure 4.2: Time relative to injury of the CT perfusion scans for each patient in the study.
4.3.2 Qualitative Findings
Uniformly amongst the acquired scans there were profound matched reductions in CBF and CBV
corresponding to regions of haemorrhagic contusion. Correspondingly, TTS, TTD, and MTT were
also all delayed within these regions and in many voxels no temporal parameters could be calcu-
lated. Within the regions of pericontusional oedema (i.e. hypodensity surrounding the haem-
orrhagic component) there was also reduced CBF and CBV, though not to the same severity
as within the contusion core, and MTT, TTS, and TTD were moderately delayed. In the ’non-
injured’ brain the CBF and CBV maps corresponded to normal white and grey matter values.
Somewhat surprisingly, the permeability maps did not show any discernible increase within the
haemorrhagic contusion, at the periphery of the contusion or at the boundary between haemor-
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rhagic tissue and oedema. Furthermore, there was no apparent increase in permeability within
the oedematous brain. Comparing the parameter maps in those patients who had two CTP scans
the regions of abnormal CBF and CBV evolved corresponding with the change in contusion size
and progression of oedema. However, there was no qualitative difference in permeability be-
tween scans performed with 48h and those performed later. A typical example of a scan in this
study is shown in Figs 4.3 to 4.7
Figure 4.3: Montage of the non-contrast CT head showing large left frontal contusion and smaller right frontal contusions
4.3.3 Quantitative Analysis
Mean parameter values within each of the eight VOIs were obtained for each scan, giving 128
measurements of each parameter. Figures 4.8 to 4.11 show the comparison between VOIs for each
parameter. Pairwise comparisons (Bonferroni corrected for multiple comparisons) found no dif-
ference in permeability between any of the VOIs (all p=1.0). This finding was unchanged when
the analysis was restricted to scans performed within 48 or 72 hours of injury only. A repeat anal-
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Figure 4.4: Montage of the cerebral blood flow (CBF) parameter map for the same patient shown in Fig 4.3. Units:
ml/100g/min
ysis using permeability maps derived with the Patlak method showed similar findings.
For CBF and CBV there were no significant differences amongst the four intra-contusional VOIs or
amongst the three peri-contusional VOIs, however both CBF and CBV were significantly higher in
pericontusional VOIs compared with contusional VOIs (p=0.015 to 10-11) and significantly higher
in the non-contusional brain as a whole (p=10-16). Correspondingly, MTT was significantly de-
layed in the contusional VOIs compared with pericontusional VOIs (p<), and both were delayed
compared to the non-contusional brain.
52
4.4. DISCUSSION
Figure 4.5: Montage of the cerebral blood volume (CBV) parameter map for the same patient shown in Fig 4.3. Units:
ml/100g
4.4 Discussion
This study has examined whether dynamic contrast enhanced CT (CT perfusion) is able to demon-
strate regions of blood brain barrier permeability in patients with traumatic brain contusions. The
analysis sought to identify whether there was an increase in BBB permeability within the haem-
orrhagic contusion core and in the pericontusional hypodensity that is typically assumed to rep-
resent tissue with vasogenic oedema. Both on qualitative assessment and quantitative analysis
of permeability maps there was no evidence of increased permeability within contusions or the
surrounding tissue. This finding was true of scans performed within 72h and those acquired later
following injury.
There are a number of potential explanations for the absence of observable BBB permeability in
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Figure 4.6: Montage of the mean transit time (MTT) parameter map for the same patient shown in Fig 4.3. Units: seconds
the present study. As has been argued previously, BBB disruption and the classical picture of va-
sogenic oedema may not be the primary mechanism of brain swelling following TBI [112, 177]. Al-
ternatively, it could be the general imaging paradigm of contrast extravasation is not sufficiently
sensitive to test for permeability in lesions with very low cerebral blood flow as was quantified
here with perfusion parameters. Iodopam, the contrast agent used in this study, has a molecular
weight of 820Da - while it is conceivable that BBB permeability may have been present but with
pore sizes sufficient to transmit only molecules with a lower molecular weight, this would con-
trast sharply with the much more profound disruption permitting passage of macromolecules of
many kDa and infiltrating inflammatory cells that is observed in preclinical models [154]. Lastly,
it is possible that the specific imaging protocol and analysis in this study may have been poorly
tuned for demonstrating increased pericontusional permeability.
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Figure 4.7: Montage of the permeability (PMB) parameter map for the same patient shown in Fig 4.3. Units: ml/100g/min
Whereas the preclinical literature contains a large number of reports demonstrating BBB disrup-
tion in a variety of TBI models using both histological and radiological quantification of contrast
extravasation, there is a relative paucity of clinical studies examining BBB integrity in TBI patients.
Early studies using gadolinium contrast enhanced magnetic resonance imaging in patients with
contusional TBI reported inconsistent findings. This form of imaging is not a dynamic scanning
technique wherein there are a series of acquisitions but a standard single pre- and post-contrast
scan are performed. Lang et al [100] examined ten TBI patients with Gd-DPTA contrast MRI but
found no evidence of contrast extravasation in those imaged within four days of injury, whereas
the three patients who were imaged later that day six did show perilesional enhancement indica-
tive of contrast extravasation. A subsequent study by Kushi et al. [97] also studied ten patients
with Gd-DTPA MRI between 24-48h following injury but with post-contrast image was delayed
to 2 and 4 hours following Gd-DPTA administration; contusions in all patients exhibited some
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Figure 4.8: Comparison of cerebral blood flow amongst the VOIs
degree of enhancement. These qualitative studies suggest that BBB disruption is common follow-
ing contusional TBI but that demonstration of the phenomenon may be vary dependent on scan
protocols.
The much more extensive literature on dynamic contrast enhanced perfusion CT in the context of
ischaemic stroke provides some useful insight into the current study [30]. Perfusion CT is now
standard practice in the diagnosis and management planning of ischaemic stroke and increased
peremeability associated within infarct and penumbra territories has been consistently shown
to predict haemorrhagic transformation and propensity to haemorrhage following thromboly-
sis treatment [76]. The observation of permeability in ischaemic and oligaemic tissue following
stroke suggests that perfusion CT is able to demonstrate permeability in tissue with low blood
flow.
However, there is evidence that the duration of perfusion CT scans is important in the accuracy
of permeability calculations. This arises from the fact that the contrast will arrive later at voxels
in regions of low blood flow compared with the reference AIF and therefore calculations based
on the ’first-pass’ (<90s) of contrast will be misleading. More accurate permeability quantification
can be achieved when additional scan volumes beyond 90s are incorporated and the contrast level
in blood is quasi-steady state. Specifically, Dankbaar et al. [41] have shown that acqusitions of
further scan volumes to 240s following contrast injection improves the reliability of permeability
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Figure 4.9: Comparison of cerebral blood volume amongst the VOIs
calculations compared with those based on the first-pass of contrast at up to 90s. However, the
permeability values determined from first-pass are typically in excess of those obtained from in-
clusion of the additional delayed scans and correspondingly a technique developed by the same
authors to correct perfusion scans limited to first-pass acquisitions was shown to decrease the es-
timated permeability. In a study from a separate group, permeability parameters from first-pass
and delayed acquisition were shown to be reasonably well correlated with each other (r=0.67),
with the latter being generally higher. These studies suggest that the scans used in the present
investigation, with a total acquisition time of under 120s, would be expected to over-estimate per-
meability. A software lock on the CT scanner control console prevented developing an imaging
protocol exceeding 120s. Conceivably, additional scan volumes could be obtained by concatenat-
ing a second protocol incorporating a series of delayed acquisitions. However, these additional
scans would have been incompatible with the perfusion CT software provided by the manufac-
turer and could not have been included in the analysis algorithm. The feasibility of a combined
study to compare perfusion CT with alternative modalities including dynamic perfusion MRI and
PET for assessing BBB permeability was also explored but administration of gadolinium based
contrast agents is not permitted for research participants (unless there is also a clinical indication)
and the necessary PET ligands and protocols were not established and would not have been pos-
sible to validate in a realistic time frame.
A further qualitative indicator of BBB permeability that may be observed on either perfusion
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Figure 4.10: Comparison of mean transit time amongst the VOIs
CT or CT angiography is the so-called ’spot sign’, described as a focal area of perilesional contrast
extravasation that is presumed to indicate microvascular disruption and contrast extravasation.
Similar to quantitative permeability maps, the presence of the spot sign in stroke patients is a pre-
dictor of haemorrhagic transformation and of progression of intracerebral haemorrhages [189].
In a series of 22 TBI patients studied with perfusion CT scan within six hours of injury, 9 were
reported to show contrast extravasation and this subset of patients had a higher incidence of
haemorrhagic contusion progression and greater oedema volume at 24h post-injury [77].
Although the primary objective of this study was to examine BBB permeability the perfusion pa-
rameters associated with contusions were also of interest. Profound reductions in cerebral blood
flow and blood volume were observed within contusions and to a lesser degree in pericontusional
brain. Previous studies have shown that perfusion CT can identify contusions that are not visi-
ble on plain non-contrast CT and that reductions in CBF have prognostic implications [116, 20].
The graduated concentric pattern of CBF reduction from contusion core through pericontusional
tissue to normal brain has been previously observed in TBI patients studied with a number of
perfusion imaging modalities and the volume of hypoperfused tissue, or the mean brain CBF
has been associated with outcome [143]. CBF thresholds for infarction are dependent on dura-
tion and metabolic demand but CBF below approximately 16-18 ml/100g/min results in arrest
of neuronal electrical activity and infarction after several hours; CBF below 12 ml/100g/min is
associated with loss of membrane function and ion homeostasis [13]. In the present study median
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Figure 4.11: Comparison of permeability amongst the VOIs
CBF in the contusion VOI was around the 18ml/100g/min threshold suggesting that this tissue is
at risk of infarction. CBF in pericontusional hypodense tissue VOI was significantly higher than
in respective contusion VOI and approximately in the oligaemic range considered as penumbral
tissue in the context of stroke; here cells may be inactive but remain viable and the tissue is po-
tentially salvageable. However, the application of threshold values derived from stroke studies
in TBI requires further validation. The burden of hypoperfusion or ischaemic brain demonstrated
on perfusion CT has been shown to predict outcome following TBI, similar to the findings of ear-
lier PET studies [20].
4.5 Summary and Context
Perfusion CT, according to the protocol used in this study, was unable to demonstrate BBB per-
meability related to brain contusions. The haemorrhagic core of contusions are associated with
significantly reduced CBF and CBV to levels comparable with ischaemic thresholds and pericon-
tusional brain has parameters similar to those observed in stroke penumbra.
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4.5.1 Hypotheses
• H3: Dynamic contrast enhanced computed tomography can quantify the severity of BBB
permeability in the vicinity of brain contusions.
Based on the current evidence this hypothesis is not accepted
• H4: Maximal BBB permeability is observed at around 72h following injury.
There was insufficient evidence to evaluate this hypothesis
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Chapter 5
Study III - Pericontusional
Inflammation: Cytokine,
Chemokines, and Growth Factors
5.1 Overview
Cerebral contusions frequently enlarge over the several days following traumatic brain injury
(TBI), involving a combination of haemorrhagic progression of the lesion core together with an
expanding volume of vasogenic and cytotoxic oedema. These phenomena exacerbate local tissue
destruction and cell loss, and also contribute to global secondary injury through raised intracra-
nial pressure, brain shift, and ultimately uncal or transtentorial herniation [96].
The important contribution of inflammatory signalling to both secondary brain injury in the acute
phase and later reparative processes has been increasingly recognised as the concept of central
nervous system (CNS) immune privilege has been challenged and reconsidered over recent years.
Evidence from in vitro and animal models has highlighted the role of cytokines, chemokine and
growth factors in secondary injury following TBI [70].
Previous microdialysis studies have provided evidence for a canonical temporal sequence of im-
mune mediators in patients with a diffuse pattern of TBI. Further, systemic administration of IL-1
receptor antagonist (IL1ra) modified the cerebral immune response in a pilot randomised con-
trolled clinical trial of patients with diffuse TBI, suggesting potential as a novel pharmacological
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intervention. However, it remains unclear whether a similar or distinct pattern of cytokine and
chemokine expression is apparent in the pericontusional brain of focal TBI patients; characterising
this localised response will be essential to successfully developing therapies directed at immune
mediators.
Furthermore, specific cytokines and growth factors have been strongly implicated in the com-
ponent of the inflammatory response that promote blood brain barrier permeability. In particular,
Vascular Endothelial Growth Factor (VEGF) has been shown to disrupt the synthesis and forma-
tion of tight junction proteins, and VEGF antagonists reduce oedema following experimental TBI
[179, 190]. The end effector of VEGF distrupting the BBB is MMP-9. Both VEGF and MMP-9 have
been found at high concentrations in contusionectomy samples from TBI patients [74]. It has not
been demonstrated in vivo whether there is spatially localised expression of VEGF in the vicinity
of contusions.
In this study, I have undertaken targeted microdialysis monitoring of pericontusional brain re-
gions in TBI patients to define the localised expression of selected cytokines, chemokines, and
growth factors. To control for the contribution of catheter insertion to the immune response we
have simultaneously monitored radiologically normal brain in each patient for comparison.
5.2 Methods
5.2.1 Recruitment and Monitoring
Adult patients with TBI requiring neurointensive care and invasive monitoring were eligible for
recruitment to the study. Invasive neuromonitoring was inserted at two sites for each patient
with the intention of having a microdialysis catheter within radiologically ’normal’ white mat-
ter and another within pericontusional brain but avoiding the haemorrhagic core. On admission
a triple-lumen cranial access device (Technicam, Newton Abbott, UK) was placed in the right
or left frontal region as standard. An intracranial pressure (ICP) monitor (Codman, Raynham,
MA, USA), a brain tissue oxygen probe (Licox Neurosciences, Andover, UK), and a microdialysis
catheter (CMA 71, 100kDA molecular weight cut-off) perfused with 3.5% (w/v) Human Albumin
Solution (Pharmacy Manufacturing Unit, Ipswich Hospital NHS Trust, Ipswich, UK) in central
nervous system perfusion fluid, were introduced via the access device. Following assent, up to
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three further invasive monitors, at least one of which was a microdialysis catheter (CMA 71 and
perfused with 3.5% albumin solution, as above) were placed in proximity to a contusion, either
via a second cranial access device or twist drill holes. If the first set of monitors happened to be
placed adjacent to a contusion the second set were inserted in radiologically normal brain on the
contralateral frontal region. In patients requiring an emergent craniotomy for an acute subdural
haematoma the pericontusional monitoring was placed adjacent to underlying contusions under
direct vision at the end of surgery, tunnelled through the scalp.
5.2.2 Sample Analysis
Hourly microdialysates were pooled into 8-hourly samples. All samples were analysed using
the Milliplex Multi-Analyte Profiling Human Cytokine 42-plex analyte premixed kit (Millipore,
St Charles, MI, USA) according to the manufacturers’ instructions. All samples were assayed in
duplicate wells (25 microL per well) and the mean of these results was used. The plates were
read using a Luminex 200 analyser (Luminex Corporation, Austin, TX, USA) running STarStation
software (Applied Cytometry Systems, Sheffield, UK). Protein concentrations were calculated by
reference to an eight-point spline fit curve for each cytokine or chemokine.
5.2.3 Statistical Analysis
The temporal course of each cytokine was fitted with a generalised additive model including
site of monitoring as a fixed factor and a random intercept for each patient. Ten-knot cubic
spline bases were employed and the restricted maximum likelihood criterion was optimised to
obtain the best fit. An F-test was performed for each cytokine to assess if there was a difference
in concentration-time course between injured and non-injured brain. To examine the broader
trends in cytokine expression and their relationship to time from injury and site of monitoring
a multivariate dimension reduction technique, namely partial least squares analysis (PLS) based
on further pooling the microdialysis samples into two groups: within 72h of injury and later
than 72h. The PLS was performed with the non-linear iterative partial least squares (NIPALS)
algorithm, which is tolerant of missing values in the data, using the mixOmics package (v6.1.0,
https://cran.r-project.org/web/packages/mixOmics/index.html). This technique reduces the
mulitvariate data to one or two ’principal’ dimensions or factors that capture the dominant vari-
ation in the data and has previously been applied to cytokine assays from TBI patients [71]. To
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assess how well the principal factors identified in the analysis discriminated between injured and
non-injured brain a receiver-operating characteristic curve was used.
5.3 Results
5.3.1 Patients
Twelve patients (9 male; mean age 47.5 years, range 22-67 years) were enrolled (Table 5.1). Paired
microdialysis monitoring was commenced a mean of 34 hours (range 16-44) following injury. Two
patients died during their intensive care treatment due to refractory intracranial hypertension.
Age Sex Mechanism GCS Pupils Marshall Evacuated SDH GOS
28 M Fall 8 +/+ 2d - 4
67 M Fall 6 +/+ 5b Right 3
67 M Pedestrian RTA 10 +/+ 2c - 3
59 F Fall 12 +/- 2d - 1
65 M Fall 11 +/+ 2d - 4
55 M RTA 9 +/+ 5b Left 5
42 F Fall 3 -/+ 5b Left 3
30 M RTA 7 +/+ 5b Right 5
22 M Assault 8 +/+ 5b Right 4
42 M Fall 7 +/+ 5b Left 5
51 M Fall 9 +/+ 2d - 1
42 F Fall 5 -/+ 2d - 3
Table 5.1: Details of patients in the study. Marshall Category 2c indicates multiple unilateral contusions, 2d indicates
bilateral contusions, category 3 indicates contusions with basal cistern effacement, and 5b indicates evacuated
subdural haematoma. GCS: Glasgow Coma Scale, GOS: Glasgow Outcome Score (at 6 months following
injury)
5.3.2 Univariate analysis
Generalised additive models for each of the 42 cytokines assayed, together with F-tests to com-
pare the two monitoring sites for significant differences in time-concentration curves are shown
in Fig 5.1. The majority of the cytokines exhibited largely monotonic time courses of decreasing
concentration over the monitoring period. Exceptions to this pattern were IL-1a, IP-10, PDGFAA,
and both IL-1ra and MCP-3 in pericontusional brain, all of which were observed to have a peak
concentration between 48-96h following injury. EGF, FLT-3 ligand, Fractalkine, GM-CSF, IFN-
g, IL-1a, IL-1b, IL-1ra, IL-3, IL-4, IL-6, IL-7, IL-9, IL-12p40, IL-12p70, IL-15, IL-17, IP-10, MDC,
MIP-1a, MIP-1b, PDGFAA, PDGFABBB, sIL-2Ra, TGFa, TNFa, and TNFb were not found to have
significant differences in either overall concentration or temporal profile between non-injured
and injured brain. G-CSF, GRO, IL-2, IL-5, IL-10, RANTES, and sCD40L had significantly lower
concentrations at the injured monitoring site but similar temporal profiles. In contrast, Eotaxin,
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FGF-2, IFN-a, IL-8, IL-13, MCP-1 were higher in pericontusional brain but had comparable time-
course as at the control site. Concentrations of MCP-3 were significantly higher in pericontusional
brain and also appeared to have a delayed peak level compared to consistently decreasing con-
centrations in uninjured brain. VEGF was non-significantly elevated in peri-contusional brain in
the 24-48h period but thereafter was lower in the injured tissue.
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Figure 5.1: Generalised additive mixed models with cubic spline basis for each of the cytokines, with site of monitoring as
a fixed factor and patient as a random factor. Test statistic and p-value in the upper left of each chart is the
F-test comparing whether site of monitoring has a significant impact on the time-concentration curve of the
respective cytokine.
5.3.3 Multivariate Analysis
As the temporal course of the cytokines was generally ’simple’, i.e. monotonic or monophasic,
the 8-hourly samples were pooled into pre- an post-72hr pools for the multivariate analysis. Par-
tial least squares regression (PLS) of the largest component of variation (PC1, 29.2%) was related
to time from injury, conversely PC2 (9.7%) tended to segregate samples from non-injured and
injured monitoring sites. The mediators that most powerfully distinguished injured from non-
injured brain were the chemokines MCP-1, MCP-3, and IL-8.
The normalisation of variance that is undertaken prior to performing PLS can inflate noise within
the data. To examine whether cytokines/chemokines at very low abundance were biasing the
data, a repeat analysis excluded all species with maximal concentrations <10pg/ml was con-
ducted. PLS findings were substantively very similar, with no qualitative difference in the load-
ing plot.
The discrminative power of the overall cytokine expression pattern was explored using a receiver-
operating characteristics curve. The area under the curve (AUC) both for monitoring time (<72h
vs >72h) and monitoring site (’normal’ vs. injured) were approximately 0.8, which is generally
considered good or excellent discrimination.
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Figure 5.2: Loading plot of the partial least squares regression, demonstrating how each of the 42 cytokines assayed was
expressed in relation to time and monitoring site
Figure 5.3: Receiver-operative characteristics curve for the first PLS component to discriminate Time and Site of moni-
toring
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5.4 Discussion
This study has shown evidence a temporally and spatially segregated expression of cytokines and
chemokine following focal TBI. In common with previous studies in diffuse TBI most cytokines
were at their highest concentration either at the start of the monitoring period or during the first
72h from injury. Previous analysis has shown the rationale for the inference that the observed
time courses of cytokine are a genuine injury-initiated cascade, rather than entirely a catheter in-
sertion effect [69]. The present study, utilising control catheters in radiologically normal brain,
provides further confirmatory evidence that, for at least a subset of cytokines and chemokines,
the expression pattern is a consequence of the patients’ injury rather than a localised response
to the catheter. Nonetheless, for many of the cytokines demonstrating significantly different con-
centrations between injured and control brain, the temporal course of expression at both sites was
similar. This would imply that there is a degree of global injury, even within radiologically nor-
mal tissue, but that differs in degree compared with regions of focal contusion. Alternatively this
could also be inferred as evidence of a catheter insertion effect on top of which the inflammatory
response to local TBI is observed.
It is important to note that the practicalities of TBI patient management and this study meant
that we were only able to obtain two-site microdialysis samples within 24h from injury in a single
patient. A number of the cytokine and chemokine time profiles show a broadly descending con-
centration from 24h onwards. It is impossible to extrapolate when these molecules will have been
at their peak, whether there is a consistent sequence of expression within the first 24h, or whether
those species that show little difference over the time period that was observed will have been
significantly different between sites earlier following injury.
5.4.1 IL-1 family
The IL1 cytokine superfamily, which includes IL1alpha, IL1beta, IL1 receptor antagonist (ILra),
has been extensively studied in both experimental and human TBI [70]. IL1b, produced by mi-
croglia, is the prototypical pro-inflammatory cytokine and elevated levels have been shown in
blood, CSF, and ECF during the acute phase of injury, most prominently within 24h. Interest-
ingly, there was not a significant difference in IL1b concentrations between injured and control
monitoring sites, with the major caveat of having insufficient data to characterise the initial 24h
from injury. In contrast, ILra was lower in pericontusional brain in the 24-48h period, thereafter
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increasing to similar concentrations as control tissue. As has been suggested previously, it is likely
that the balance between IL1b and ILra is the determinant of the degree or severity of the local
inflammatory state. Correspondingly, in an earlier single-site microdialysis study IL1ra:IL1b ratio
was found to be significantly higher amongst patients with favourable outcome [78]. The present
investigation additionally suggests that, within individual patients, it is principally heterogene-
ity in IL1ra levels that is most marked between regions of injured and normal tissue. This would
further support the hypothesis that ILra supplementation may be an effective therapy in TBI, and
other acute brain injury conditions.
5.4.2 Chemokines
A further subset of the monitored chemokines that were notably at higher concentrations in peri-
contusional brain were those involved in promoting cellular infiltration. IL-8 (CXCL8), MCP-1
(CCL2), and MCP-3 (CCL7) are all all chemotactic factors that attract and induce migration of
neutrophils (IL-8) and monocytes (MCP-1 and -3), and also regulate macrophage function. Both
IL-8 and MCP-1 were significantly elevated from the start of monitoring, whereas MCP-3 showed
a delayed response peaking at around 72h. MCP-1 has been shown previously to be elevated in
plasma and CSF from TBI patients and in preclinical models is important in determining final
lesion volume following focal injury [148, 75]. Similarly elevated IL-8 in CSF has previously been
observed in TBI patients [93, 196]. These findings imply early cellular infiltration into pericontu-
sional tissue, which would necessitate BBB dysfunction.
5.4.3 Anti-inflammatory cytokines
IL-10 plays a central role in moderating inflammatory response, and in general exerting anti-
inflammatory effects by downregulating synthesis of pro-inflammatory cytokines and suppress-
ing the expression and activation of respective cytokine receptors [165]. In turn, IL-10 reduces
the attraction and infiltration of activated macrophages and T-cells. Furthermore, IL-10 is pro-
tective of endothelial cell function and BBB integrity. In pre-clinical TBI models an increase in
IL-10 has been observed within hours of injury, with evidence for local cerebral production rather
than influx through a permeable BBB. Studies with IL-10 knockout mice subjected to focal TBI
have shown larger lesion volumes and poorer neurological function [10]. Correspondingly, intra-
venous administration of IL-10 found reduced lesion volume and improved motor and cognitive
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recovery in both cortical impact and fluid percussion models [32]. Clinical studies of IL-10 in TBI
have not shown consistent findings. Serum IL-10 has both been reported to have no association
with severity of TBI whereas other groups have identified higher concentrations in patients with
more severe TBI and with poorer outcome [56]. Similarly, IL-10 in CSF of TBI patients has been
found to correlate with injury severity, raised intracranial pressure, and outcome, but in other
series IL-10 concentrations, though elevated, do not exhibit a relationship with BBB permeability
or mortality [56]. This heterogeneity of findings is undoubtedly multifactorial, and IL-10 levels
in particular may be significantly confounded by the extent of extra-cranial injury. Furthermore,
association of higher IL-10 concentrations with mortality and poor outcome does not necessarily
imply a deleterious effect of this cytokine. In the present study there was a significantly higher
concentration of IL-10 observed in the radiologically normal monitoring sites during the first 72h
following injury, with concentrations at both monitoring sites becoming similar after this time. Al-
ternative interpretations of this observation are that basal IL-10 synthesis is initially suppressed
in pericontusional brain following injury, or that there is an injury response of increased IL-10
expression in radiologically normal brain that is absent in proximity to contusions. In either case,
this is further evidence of a pro-inflammatory milieu localised to pericontusional brain and sug-
gests that supplementing or potentiating IL-10 as a therapeutic target merits further investigation.
5.4.4 VEGF
VEGF was noted to be expressed at similar levels in peri-contusional and control monitoring
sites in the first 48h following injury but thereafter was lower in pericontusional brain. This
finding contrasts with the extensive evidence from pre-clinical and patient studies showing the
elevated expression of VEGF in regions of focal injury as one of the key activators of BBB dis-
ruption [36, 155, 115, 69]. The expression of VEGF across the patients was heterogenous but
the reasons for a lack of clear elevation of VEGF in pericontusional brain in the present study is
unclear. One potential explanation may be the the lack of monitoring data from the initial 24h
following injury during which higher concentrations of VEGF may have been observable in the
pericontusional brain, although in animal TBI models VEGF generally peaks at day 4 from injury
[36, 155, 120, 128]. Alternatively, it is conceivable that post-traumatic VEGF expression is highly
localised to the edge of the haemorrhagic contusion and therefore even the pericontusional mi-
crodialysis catheters placed in adjacent brain were insufficiently close to detect this.
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5.4.5 Multivariate analysis
The inflammatory response to injury comprises multiple redundant pathways and molecular
interactions, and it is often by observing the concerted changes in a number of cytokines and
chemokines that gives a better impression of the overall ’system state’. Further, individual me-
diators that do not show significant univariate differences between injured and control tissue
may emerge as having more prominent roles in the context of examining covarying responses of
groups of cytokines and chemokines. In this study we have employed principal components and
partial least squares analysis, which are robust to data with a large number of observations in rel-
atively few subjects. These techniques have been used previously to show the temporal pattern
of inflammatory response in diffuse TBI, and also to examine the effect of intervention with re-
combinant IL1ra delivered subcutaneously in these patients. Rather than examining the response
to intervention of a single mediator, PCA and PLS give a more general view of how the network
of inflammatory pathways is perturbed, which also permits more nuanced interpretations as the
role of individual cytokines may be pro- or anti- inflammatory depending on the covariation in
changes of other cytokines.
In the present study the PLS analysis demonstrates that the pericontusional tissue exhibits a
pro-inflammatory signature, with covarying increases in typical pro-inflammatory cytokines (e.g.
IL-8) and concomitant reduction in anti-inflammatory cytokines (e.g. IL-10), Furthermore, this
covariation in pro- and anti-inflammatory cascades is primarily seen in the early (<72h) phase of
secondary injury.
Increased concentrations of pro-inflammatory cytokines and chemokines in pericontusional brain
aligns with findings from experimental TBI models that these are the sites of predominant inflam-
matory cell invasion [70]. These data confirm that the inflammatory response in contusional TBI
is spatially heterogenous in regions of radiologically normal and contusional/pericontusional
brain. This is important in predicting the likely benefits of anti-inflammtory therapies such as
IL-1ra [72].
5.4.6 Limitations
There are inherent statistical difficulties in examining large amounts of data collected from a rel-
atively smaller number of subjects, and there is a risk of drawing spurious ’significant’ findings
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that are observed by chance. As such the cytokines and chemokines identified as significantly
different between monitoring sites need corroboration in larger studies, but in general accord and
are supported by findings in prior reports. The PLS analysis also goes some way to mitigating
these statistical concerns and highlights the covarying changes of mutliple mediators at the sites
of injury. As already mentioned, the absence of data from the first 24h following injury is a major
limitation, particularly as it is likely during this period that a number of the signalling molecules
will be at their highest concentrations.
5.5 Summary and Context
This study has demonstrated evidence for a localised, early, pro-inflammatory response within
pericontusional brain typified by reduced IL1ra:IL1b ratio, increased expression of chemokines,
and relatively lower concentrations of anti-inflammatory cytokines. The data did not show evi-
dence for localised VEGF expression in pericontusional brain.
5.5.1 Hypotheses
• H5: Pericontusional brain exhibits a pro-inflammatory tissue signature following TBI.
Based on the current evidence this hypothesis is accepted.
• H6: Vascular Endothelial Growth Factor exhibits higher expression in pericontusional brain
following TBI.
Based on the current evidence this hypothesis cannot be accepted.
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Chapter 6
Study IV - Matrix Metalloproteinases
in Pericontusional Brain
6.1 Overview
Matrix metalloproteinases (MMP) are a family of extracellular and cell-surface attached pro-
enzymes that when activated target a wide range of protein substrates and are involved in di-
verse signalling pathways [121]. Preclinical models have demonstrated that MMPs have a central
role initiating proteolysis of the tight junctions that bind the apical surface of brain endothelial
cells and form the principal component of the blood brain barrier [202, 29]. Tissue obtained at
contusionectomy surgery and post-mortem suggest increased expression of MMP-9 in pericontu-
sional brain, but it is not clear if this is a consequence of tissue necrosis or an antecedent cause of
contusion and brain oedema progression [186].
Early evidence from previous microdialysis studies indicates elevated expression of MMP-9 in
the traumatised human brain, but it is not clear if this is a global response or concentrated in ar-
eas of contusional injury.
This is a further paired microdialysis study with catheters targeted at pericontusional brain and
another placed in radiologically normal brain to assess whether MMP expression is localised in
the pericontusional region in vivo.
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6.2 Methods
6.2.1 Recruitment and Monitoring
Adult patients with TBI requiring neurointensive care and invasive monitoring were eligible for
the study. Invasive neuromonitoring was inserted at two sites for each patient with the inten-
tion of having a microdialysis catheter within radiologically ’normal’ white matter and another
within pericontusional brain but avoiding the haemorrhagic core. Microdialysis catheters (CMA
71, 100kDA molecular weight cut-off) were perfused with 3.5% (w/v) Human Albumin Solution
(Pharmacy Manufacturing Unit, Ipswich Hospital NHS Trust, Ipswich, UK) in central nervous
system perfusion fluid. If the first set of monitors happened to be placed adjacent to a contusion
the second set were inserted in radiologically normal brain on the contralateral frontal region.
In patients requiring an emergent craniotomy for an acute subdural haematoma the pericontu-
sional monitoring was placed adjacent to underlying contusions under direct vision at the end of
surgery, tunnelled through the scalp.
6.2.2 Sample Analysis
Microdialysate was pooled 8-hourly and then assayed in duplicate for MMP-1, MMP-2, MMP-
7, MMP-9, and MMP-10 using the five-plex Milliplex Multi-Analayte Profiling Human MMPII
panel (Millipore, St. Charles, MI, USA) according to the manufacturers’ instructions. All samples
were assayed in duplicate wells (25 microL per well) and the mean of these results was used. The
plates were read using a Luminex 200 analyser (Luminex Corporation, Austin, TX, USA) running
STarStation software (Applied Cytometry Systems, Sheffield, UK). Protein concentrations were
calculated by reference to an eight-point spline fit curve for each MMP.
6.2.3 Contusion Volume
The routinely performed CT scans for each patient were analysed with the stereological method,
described earlier in this work, to determine the volume of haemorrhagic contusion and adjacent
oedema using a 5mm grid spacing. The change in core, oedema, and total lesion volume over the
initial 72h from injury was estimated by comparison of volumes on the scan performed closest to
72h from injury and the patient’s baseline admission imaging.
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6.2.4 Statistical Methods
To mitigate the effects of different monitoring periods in each patient the mean concentrations of
each MMP in the first 72 hours following injury (<72h) and in the subsequent 72 hours (>72h)
were calculated for each patient. Repeated measures analysis of variance (ANOVA) with MMP
concentration as the dependent variable, and site of monitoring (’Normal’ vs. Injured) and time
(<72h vs. >72h) as the independent variables, was then applied for each MMP separately. Univari-
ate subgroup comparisons were analysed with the independent samples T-test. All calculations
were performed in R (v3.0.2, www.r-project.org) and considered significant at 5%.
6.3 Results
6.3.1 Patients
Twelve patients (10 male; mean age 46 years, range 21-65 years) were enrolled (10 in common with
Study III). Paired microdialysis monitoring was commenced a mean of 36 hours (range 16-48) fol-
lowing injury. No complications attributable to the additional study monitoring were observed.
Two patients died during their intensive care treatment due to refractory intracranial hyperten-
sion. Of the ten patients who survived, seven had a favourable outcome (GOS 4-5, moderate
disability or good recovery) at six months follow-up and three were severely disabled (GOS 3)
Age Sex Mechanism GCS Pupils Marshall Evacuated SDH GOS
28 M Fall 8 +/+ 2d - 4
67 M Fall 6 +/+ 5b Right 3
31 M Fall 5 -/+ 3 - 3
67 M Pedestrian RTA 10 +/+ 2c - 3
59 F Fall 12 +/- 2d - 1
65 M Fall 11 +/+ 2d - 4
55 M RTA 9 +/+ 5b Left 5
42 F Fall 3 -/+ 5b Left 3
30 M RTA 7 +/+ 5b Right 5
22 M Assault 8 +/+ 5b Right 4
42 M Fall 7 +/+ 5b Left 5
48 M Assault 10 +/+ 2d - 1
Table 6.1: Demographics of patients in the study. Marshall Category 2c indicates multiple unilateral contusions, 2d in-
dicates bilateral contusions, category 3 indicates contusions with basal cistern effacement, and 5b indicates
evacuated subdural haematoma. GCS: Glasgow Coma Scale, GOS: Glasgow Outcome Score (at 6 months
following injury)
6.3.2 Temporal course of MMP expression
Mean time-concentration plots for each MMP assayed are shown in 6.1. Examples of catheter
placement and corresponding individual time courses of the five MMPs assayed are shown in
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6.2. Although in some patients MMP-2 concentrations gradually increased in pericontusional
brain, overall concentrations of MMPs -1, -2, and -10 were similar at both sites during the mon-
itoring period and did not demonstrate consistent temporal trends across the cohort of patients.
There was a gradual increase in the concentration of MMP-7 at both monitoring sites, but this was
not observed in all patients.
In contrast, MMP-9 concentrations were consistently higher in the injured brain compared with
radiologically normal brain. The highest concentrations of MMP-9 were observed at the earliest
monitoring times (i.e. <24 hours) within injured brain. Thereafter, MMP-9 concentrations de-
creased but remained higher within injured brain compared with radiologically normal brain to
72 hours post-injury, and beyond.
Figure 6.1: Mean time-concentration curves for each MMP across all patients. Error bars represent standard error of the
mean (SEM)
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Figure 6.2: Representative examples of patient CT scans demonstrating catheter placement and corresponding time-
concentrations curves for each MMP. Top: patient 5, bottom: patient 2. Red circles highlight the tip of the
microdialysis catheter in pericontusional brain; green circles indicate the microdialysis catheter in ’normal’
brain.
Mean concentrations of the five MMPs in normal and injured brain in the periods <72hrs and
>72hrs following admission are shown in 6.3. Repeated measures ANOVA showed no significant
difference in MMP-1, -2, -7, or -10 concentrations between normal or injured sites, and no effect
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of time. However, MMP-9 concentrations were significantly higher in pericontusional brain com-
pared with radiologically normal brain (p=0.03) and were also significantly higher in the early
monitoring period (<72hrs) compared with later time-points (>72hrs, p=0.04).
There were no significant differences (p>0.05) in concentrations of any of the assayed MMPs
when the cohort of patients was divided into two groups based either on presenting severity
of TBI (GCS <8 vs. >8), whether or not the patient had a SDH evacuated, and functional outcome
(GOS 1-3 vs. 4-5).
Figure 6.3: Group mean (SEM) concentration of each MMP at each monitoring site <72h following injury and >72h injury.
Repeated measures ANOVA demonstrated significant differences between monitoring sites (p=0.03) and be-
tween monitoring periods (p=0.04) for MMP-9; no significant differences were observed for MMP-1, -2, -7 and
-10 (see text for full details).
6.3.3 Pericontusional MMP-9 and contusion progression
Comparison of pericontusional MMP-9 expression and the volume change of the total contu-
sion lesion (haemorrhagic core and oedema) is shown in Fig 6.4, and is suggestive of an asso-
ciation although there was no statistically significant correlation (r=0.48, p=0.112). Interestingly,
the clear outlier in this plot (indicated by the highlighted point) represents a patient who devel-
oped marked cerebral oedema and refractory intracranial pressure as a consequence of extensive
venous thrombosis rather than contusion progression per se. With this patient excluded there
was a significant correlation between pericontusional MMP-9 expression and the magnitude of
contusion volume expansion (r=0.72, p=0.013).
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Figure 6.4: Scatter plot of pericontusional MMP-9 concentration and corresponding volume change of the total lesion
(haemorrhagic core and oedema combined) over the initial 72h from injury. The red point indicates a patient
with refractory cerebral oedema and intracranial pressure due to venous sinus thrombosis; with this patient
excluded there is a significant correlation (r=0.72, p=0.013; see text)
6.4 Discussion
This study has demonstrated that there is a specific, early, and localised increase in MMP-9 con-
centrations within pericontusional brain following TBI. Although the concentration of MMP-7
appeared to gradually increase over the monitoring period in both injured and uninjured brain
no significant differences were found in the concentrations of MMP-1, - 2, -7, -10 with respect to
monitoring site or time. Comparing patient groups based on presenting GCS, presence of sub-
dural haematoma requiring evacuation, and functional outcome, found no significant differences
in MMP concentrations. It is unsurprising that in a relatively small cohort of patients there is
no statistical relationship between interstitial MMP concentrations and clinical features that are
dependent on a plurality of factors. However, there was provisional evidence for an association
between MMP-9 expression and the degree of contusion expansion, albeit having excluded one
patient with apparent confounding factors that were the cause of progressive cerebral oedema.
Our findings are in accordance with preclinical evidence that MMP-9 expression is increased in
perilesional brain following experimental brain contusion, and in these models corresponds with
the development of BBB permeability and expansion of the final lesion volume[153, 64]. Grosslete
et al. and Zheng at el. have previously reported elevated levels of MMP-9 in CSF sampled acutely
from TBI patients via ventriculostomy, with comparable temporal profiles demonstrating great-
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est concentrations in the first sample at 24 hours post-injury followed by a decline, but remaining
higher than control CSF for at least 72 hours [60, 192] Vilalta et al. studied four patients with
diffuse brain injury using microdialysis and found similar early elevation of cerebral MMP-9 con-
centrations [187]. More recently, Roberts et al. conducted a single site microdialysis study of
MMP-1, -2, -3, -7, -8, and -9 in eight TBI patients with a mixture of diffuse and focal injuries; simi-
larly to the present study, they found MMP-9 was increased early following injury and thereafter
declined [138].
The present data both corroborate these temporal MMP-9 profiles in a larger cohort of TBI pa-
tients, and adds the important new finding that in patients with predominantly focal or contu-
sional injury the MMP-9 response is localised to perilesional brain. The paired catheter design
means it is far less likely that the observed changes in MMP-9 are attributable to artefact from
catheter insertion, as a similar effect would have been observed at both monitoring sites. The
evidence from this study goes some way to supporting the hypothesis that the mechanisms of
MMP-9 induced BBB disruption and oedema elucidated in animal models are also relevant in hu-
man TBI. The observed association between MMP-9 concentration and the increase in contusion
and oedema volume further backs an important role for this enzyme in clinical TBI, though the
finding is still insufficient to infer a causative role.
Both previous microdialysis studies have found evidence for increased cerebral expression of
MMP-2 following TBI, although Vialta et al. identified an early peak similar to MMP-9, whereas
in the later study by Roberts et al. MMP-2 concentration was initially low and increased at around
48 hours post-injury, with a subsequent decrease [187, 138] In the present study patients exhib-
ited variable MMP-2 responses, with no consistent spatiotemporal pattern emerging on averaging
across the cohort. Interestingly, an earlier study of contusion resection tissue also found MMP-
2 concentrations that varied widely and the resulting overall difference in expression compared
with control patient samples was modest [186]. Together, these findings suggest MMP-2 concen-
trations may be significantly elevated in only a subset of TBI patients; whether this is a function of
injury severity or other patient-specific clinical factors will require larger studies to resolve. The
relative importance of MMP-2 compared with MMP-9 in the pathogenesis of contusion expansion
and brain oedema is unclear, and there is conflicting evidence on the role of MMP-2 in exacerbat-
ing lesion volume from different brain injury models [64, 201]. However, as both MMP-2 and
-9 are gelatinases and act on similar substrates they may represent redundant pathways in post-
traumatic proteolytic breakdown of the BBB. If interventions targeted at MMP activity are to be
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successful a more complete understanding of the role of MMP-2 will be essential, particularly as
evidence from preclinical TBI models suggests that MMP-2 and MMP-9 show different responses
to current therapies such as hypothermia [176].
Induced hypothermia has been shown to attenuate MMP-9 expression in rodent TBI and stroke
models but as yet this phenomenon has not been investigated in human patients [176, 103]. De-
spite a number of randomised trials, therapeutic hypothermia has not been conclusively shown to
improve outcome following TBI, though its use to control intracranial pressure remains widespread
[58, 163]. Conceivably, targeting hypothermia to patients with increased MMP-9 expression may
be a method to select the subgroup of patients in which the benefits of this treatment outweigh its
deleterious effects.
MMP inhibitors have been investigated as promising therapies for a number of diseases, most
notably in metastatic cancer. However, despite successful preclinical findings, early phase clinical
trials in cancer patients have proven disappointing due to lack of efficacy and excessive adverse
effects [159]. Of interest, tetracycline antibiotics, most notably doxycycline, inhibit MMP-2 and -9
through chelation of the zinc ion in the catalytic site [157]. Doxycycline at sub-antimicrobial doses
has been shown to be of benefit in periodontitis, likely via its effect on MMP-9 activity [133]. On
the same basis, doxycycline has also been suggested as a treatment to stabilise the growth of ab-
dominal aortic aneurysms, although the evidence to date is conflicting [107]. Currently available
MMP inhibitors are not selective for specific subtypes but at the same time are not equally active
on all members of the enzyme family; combined with redundancy in MMP pathways this may be
an explanation for the limited efficacy of MMP inhibitors in clinical studies to date.
This study suggests that MMP-9 may be a therapeutic target to reduce lesion progression and
brain swelling in contusional TBI. Investigating the efficacy of MMP inhibitors in this context will
first require further detailed studies of the association between pericontusional MMP-9 concentra-
tion, contusion expansion and vasogenic oedema, intracranial pressure and treatment intensity,
and cerebral metabolism, to establish robust measures of efficacy. Human studies to date indi-
cate that the useful therapeutic window for MMP-9 inhibition following TBI may extend up to 72
hours from injury, but it is likely that any agent will be most effective at minimising brain oedema
and contusion expansion if administered as acutely as possible. Defining the appropriate dura-
tion of MMP inhibition will also need to consider the later role these enzymes have in post-injury
central nervous system repair.
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6.4.1 Limitations
This study has a number of limitations. Firstly, no patient was monitored within the first 12 hours
of injury and therefore the expression pattern of MMPs in the very acute stage remains uncer-
tain. Secondly, MMP activity is regulated by endogenous Tissue Inhibitors of Metalloproteinase
(TIMP) proteins which bind with latent and activated MMPs [121]. Although MMP-TIMP com-
plexes would likely exceed the 100kDa cut-off of the CMA 71 microdialysis catheter, it cannot be
determined from the present data whether all MMP-9 assayed was enzymatically active; future
studies to address this question will be challenging due to low absolute amount of protein recov-
ered with microdialysis. Third, the findings of the current study injury do not speak to whether
MMP concentrations will display similar temporal profiles in patients with a predominantly dif-
fuse axonal injury pattern on initial CT.
6.5 Summary and Context
This study has shown that MMP-9 is upregulated in pericontusional brain compared with radio-
logically normal brain and this expression occurs early following injury. The observed time course
would suggest important upstream regulators of MMP-9, such as VEGF, are likely maximally ex-
pressed within the first few hours of injury and would be an explanation for why these were not
observed in the cytokine study described in the previous chapter. The results provide preliminary
evidence for an association between MMP-9 and the severity of contusion and oedema progres-
sion.
6.5.1 Hypotheses
• H7: MMP-9 shows increased expression early following TBI and is primarily localised to
pericontusional brain.
Based on this study this hypothesis is accepted.
• H8: MMP-2 shows delayed increase in expression following TBI that is also primarily lo-
calised to pericontusional brain. There was insufficient evidence to accept this hypothesis.
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Study V - Pericontusional Nitric
Oxide
7.1 Overview
Nitric Oxide (NO) is a highly diffusable radical gas molecule that is synthesised from the amino
acid L-arginine by the nitric oxide synthase (NOS) family of enzymes [57]. NO has a variety
of roles in neurotransmission and synaptic modulation, intracellular signalling, neuroinflamma-
tory cascades, and in the regulation of cerebrovascular tone and cerebral blood flow [57, 34].
Three NOS isoforms have been identified in humans: endothelial NOS (eNOS), neuronal NOS
(nNOS), and inducible NOS (iNOS). Both eNOS and nNOS are constitutively expressed in the
brain whereas iNOS is upregulated in response to injury [175, 57].
Broadly, cerebral autoregulation comprises mechanoregulation (maintenance of constant flow
with varying systemic arterial blood pressure) and chemoregulation (maintenance of flow in re-
sponse to changing CO2 concentrations due to metabolic pertubations and during hypoxia) [57].
NO is a key mediator of both CO2 chemoregulatory pathways [102] and is necessary for augment-
ing blood flow in response to hypoxia [166]. In the context of TBI this would suggest a beneficial
role for NO in maintaining constant CBF under the stress conditions following injury, and that
relative NO depletion may be a factor in post-injury ischaemia and loss of flow-metabolism cou-
pling [57].
However, excess NO may be a factor in post-traumatic dysautoregulation, vasoplegia and va-
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sodilatation, and hyperaemia, with consequent raised intracranial pressure, and has also been
identified as a component of the pathway resulting in blood-brain barrier breakdown by VEGF
[52, 34, 147, 188]. Furthermore, following cerebral insults, it has been shown that eNOS can be-
come uncoupled from its cofactor tetrahydrobiopterin, resulting in the alternative production of
superoxide, a radical that is neurotoxic. Superoxide may in turn react with NO to form peroxyni-
trite that is also neurotoxic and depletes available NO.
NO itself is difficult to assay in clinical samples owing to its short half life. However, assay-
ing concentrations of stable NO metabolites nitrite and nitrate (NO2 and NO3, collectively NOx)
is a validated method of indirectly quanitfying endogenous NO synthesis [137]. In humans, NOx
have been assayed in CSF and microdialysate of diffuse-injury pattern TBI patients. A series of
eleven TBI patients who underwent regular CSF sampling suggested a peak in NOx at approx-
imately 24h following injury [178]. The concentration of NO was correlated with that of IL-8,
suggesting that NO levels may reflect the degree of post-TBI inflammatory burden [178]. In a
pilot study of twelve brain injury patients (11 TBI), studied with microdialysis, extracellular NOx
concentration was found to be correlated with higher cerebral glucose and lower lactate/pyruvate
ratio, suggesting a beneficial metabolic effect of higher NO concentrations [24]. However, a more
recent microdialysis study in eleven TBI patients found significantly higher NO concentrations
within the first 48h from injury amongst patients who died compared with survivors, suggesting
that NO is a either a marker of more severe primary insult or that it potentially contributes to
secondary injury and likelihood of poor outcome [174].
A number of factors may explain the contrasting findings in clinical TBI studies of NOx, includ-
ing temporal and spatial heterogenity of NOx concentrations in relation to catheter placement.
In this study we have examined whether there are spatiotemporal differences in NO production
following contusional TBI using targeted pericontusional microdialysis catheters.
7.2 Methods
Adult patients with TBI requiring neurointensive care and invasive monitoring were enrolled.
Neuromonitoring was inserted at two sites for each patient with the intention of having a micro-
dialysis catheter within radiologically ’normal’ white matter and another within pericontusional
brain but avoiding the haemorrhagic core. On admission a triple-lumen cranial access device
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(Technicam, Newton Abbott, UK) was placed in the right or left frontal region as standard. An
intracranial pressure (ICP) monitor (Codman, Raynham, MA, USA), a brain tissue oxygen probe
(Licox Neurosciences, Andover, UK), and a microdialysis catheter (CMA 71, 100kDA molecular
weight cut-off) perfused with 3.5% (w/v) Human Albumin Solution (Pharmacy Manufacturing
Unit, Ipswich Hospital NHS Trust, Ipswich, UK) in central nervous system perfusion fluid, were
introduced via the access device. Following assent, up to three further invasive monitors, at least
one of which was a microdialysis catheter (CMA 71 and perfused with 3.5% albumin solution, as
above) were placed in proximity to a contusion, either via a second cranial access device or twist
drill holes. If the first set of monitors happened to be placed adjacent to a contusion the second
set were inserted in radiologically normal brain on the contralateral frontal region. In patients
requiring an emergent craniotomy for an acute subdural haematoma the pericontusional mon-
itoring was placed adjacent to underlying contusions under direct vision at the end of surgery,
tunnelled through the scalp. Hourly microdialysates were pooled into 8-hourly samples.
7.2.1 NOx Assay
Nitric Oxide is a short lived molecule but its products NO2 and NO3 are stable and can be readily
assayed. Collectively these are termed NOx. Total nitrate and nitrite (NOx) were determined
by injection of 5microL of microdialysate into a purge vessel containing a solution of vanadium
(III) chloride (50mmol/L) in hydrochloric acid (1 mol/L) at 95◦C continuously purged with ni-
trogen gas. This chamber was connected to a Sievers 280i Nitric Oxide Analyser (GE Analytical
Instruments, Boulder, CO, USA). The vanadium (III) chloride reconverts the NOx to nitric ox-
ide which then reacts with ozone (O3) within the analyser. This forms nitrogen dioxide which
can be readily detected by chemiluminescence against standards of known concentration. This
specialist assay was performed by Mr Richard Shannon. All samples were processed in duplicate.
7.2.2 Statistical Analysis
Paired NOx concentrations at each pooled time point within each patient were compared with a
linear mixed model including a random effect for each patient. The temporal course of NOx con-
centrations were compared with generalised additive mixed models (GAMM) including a ran-
dom effect for each patient. Smooth terms were composed of a ten-knot cubic regression spline
basis and optimised using restricted maximum likelihood (REML). Metabolites assayed hourly
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at the bedside (glucose, lactate, pyruvate, glycerol, and glutamate) were averaged to correspond
with each pooled sample and then comparison of NOx with these metabolites was performed
with similar statistical tests. All analysis was conducted in R v3.4.3 and statistical significance
was set at p<0.05.
7.3 Results
Eleven patients (nine male) were included. Demographics are shown in Table 7.1. A total of
185 eight-hourly pooled samples were assayed for NOx concentration with overall mean 19.18
[SD 11.0] micromol/L, and median 16.64 micromol/L. Taking together all sample points, linear
mixed model analysis showed that NOx concentration was moderately significantly higher in the
radiologically ’normal’ or uninjured sites (Figure 7.1 mean difference 2.43 micromol/L, 95% CI
0.04-4.82, p=0.047), with a significant effect of time (p<0.001).
Age Sex Mechanism GCS Pupils Marshall Evacuated SDH GOS
28 M Fall 8 +/+ 2d - 4
67 M Fall 6 +/+ 5b Right 3
31 M Fall 5 -/+ 3 - 3
67 M Pedestrian RTA 10 +/+ 2c - 3
59 F Fall 12 +/- 2d - 1
65 M Fall 11 +/+ 2d - 4
55 M RTA 9 +/+ 5b Left 5
42 F Fall 3 -/+ 5b Left 3
30 M RTA 7 +/+ 5b Right 5
22 M Assault 8 +/+ 5b Right 4
42 M Fall 7 +/+ 5b Left 5
Table 7.1: Demographics of patients in the study. Marshall Category 2c indicates multiple unilateral contusions, 2d in-
dicates bilateral contusions, category 3 indicates contusions with basal cistern effacement, and 5b indicates
evacuated subdural haematoma. GCS: Glasgow Coma Scal, GOS: Glasgow Outcome Score (at 6 months
following injury)
To characterise the temporal trend a GAMM model was used with a fixed effect of moni-
toring site and smooth term for time, with per-patient random effect. The mean trend in NOx
concentrations at each time point from the random-effect GAMM model at ’uninjured’ and ’in-
jured’ monitoring sites is shown in Figure 7.2. NOx concentrations showed a significant decrease
over time, a trend that was observed similarly at both monitoring sites. There was no significant
difference in the temporal trends between paired noninjured and injured catheters. Binning the
samples into <72h and >72h from injury showed a significant difference in time using a linear
mixed model (mean difference 6.73 micros mol/L, 95% CI 4.08-9.38, p<0.001)
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Figure 7.1: Comparison of NOx concentrations . Mean NOx concentration at each 8-hourly pooling period across the
patients
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Figure 7.2: Time course of NOx concentrations. Smoothed mean NOx concentration at uninjured and injured monitoring
sites from the GAMM model. Shaded region indicates pointwise standard error.
There were significant relationships between the concentrations of NOx and the other metabo-
lites. The strongest association was seen with pyruvate (r=0.322, p<0.001), followed by lactate
(r=0.258, p<0.001), and glucose (r=0.183, p=0.020). There was no significant correlation between
NOx and either glycerol (r=-0.117, p=0.135) or glutamate (r=0.012, p=0.909). The functional re-
lationship between NOx and glucose, pyruvate, and lactate was explored further with GAMM
models including random effect terms for each patient. These models are shown in Figure 7.3.
There was no significant difference between the association of NOx and glucose or pyruvate
within noninjured and injured brain but there was a significant difference in trend for lactate,
which increased for more rapidly with rising NOx at the injured monitoring sites compared with
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the control catheters.
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Figure 7.3: Functional relationship between NOx and energy metabolites. GAMM models of (A) glucose, (B) Pyruvate,
(C) lactate, and (D) lactate/pyruvate ratio against NOx in noninjured and injured monitoring sites.
7.4 Discussion
This study has shown that interstitial or extracellular fluid concentrations of NOx are highest
early following TBI and gradually reduce over the course of several days of monitoring. This find-
ing is consistent with previous human microdialysis and CSF studies [24, 174]. The present data
also show statistically significant lower concentrations of NOx in pericontusional brain through-
out the period of monitoring but with a similar temporal course as in radiologically uninjured
brain within the same patient.
Similarly, in agreement with previous microdialysis studies NOx was positively correlated with
glucose, pyruvate, and lactate, but not glycerol or glutamate, both in noninjured and injured
brain. However, lactate demonstrated a much stronger positive trend in association with NOx in
pericontusional brain. Correspondingly, LPR - a measure of cellular redox state and the balance of
aerobic and anaerobic metabolism - increased with higher NOx in pericontusional brain whereas
LPR was either static or slightly decreased with increasing NOx in radiologically uninjured brain.
The association of NOx and LPR in uninjured brain corresponds with the previous study in dif-
fuse TBI, where catheters would typically be located in radiologically normal brain (as defined on
computed tomography imaging)[24]. Therefore, the present study suggests potentially differing
responses to NOx concentrations in contused brain compared with uninjured tissue or regions of
diffuse injury. While catheter sites within radiologically normal brain have been termed ’unin-
jured’ in this discussion, the fact that NOx followed a similar temporal course at both sites within
individual patients suggests this may not necessarily be true. Explanations include a component
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of diffuse injury affecting radiologically normal brain, a cerebral component of a systemic injury
response, or lastly a catheter insertion artifact. By the same token, the correlation of NOx with
energy metabolites and contrasting relationship with LPR may be an indirect association simply
as a consequence of the difference in glucose, pyruvate, and lactate between pericontusional and
radiologically normal brain.
Nonetheless, these data suggest the possibility that specific regions of the brain may have con-
trasting responses to NO supplementation following injury. Specifically, in radiologically normal
brain increased NO levels are inferred to be beneficial and improve metabolic parameters as in
the ’normal’ physiological state. However, in pericontusional regions increasing NO appears to
have a deleterious effect. This action might be hypothesised to be a consequence of NO action
on potentiating blood brain barrier permeability, exacerbating local oedema and causing more
profound microvascular ischaemia and inflammation [34, 57].
Animal studies in stroke and experimental contusional brain injury have shown that both inhaled
and intravenous NO donors reduce final lesion volume and improve functional neurological as-
sessments [86, 170]. However, there are conflicting findings that NOS inhibitors administered
shortly after controlled cortical impact also reduced oedema and final lesion volume [169]. The
present study further speaks to the fact that there is likely to be a heterogeneity of response to NO
supplementation in TBI patients, and appropriate selection of patients for proposed clinical trials
[127] based on timing and pattern of injury will be important to obtain beneficial effects rather
than exacerbating secondary insults.
7.5 Limitations
This study was in a small number of patients and therefore the significant findings should be
interpreted with some degree of caution. As discussed, the different associations between NOx
and energy metabolites may have been observed by virtue of the difference in glucose, pyruvate,
and lactate between monitoring sites. Lastly, the inference of NO synthesis from stable NOx con-
centrations does not account for NO diverted into alternative pathways, such as peroxynitrite
formation, and therefore the true relationship between in vivo NO production and the assay re-
sults is not fully characterised.
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7.6 Summary and Context
NO metabolites NO2 and NO3 are increased early following TBI in both radiologically normal
and pericontusional brain and gradually reduced over several days. There is a slight but statis-
tically significant lower mean NOx concentration in injured brain. NOx is positively correlated
with pyruvate and lactate, but with heterogenous responses between uninjured and injured brain
and resulting in contrasting relationships between LPR and NOx at radiologically normal and
injured monitoring sites.
7.6.1 Hypotheses
• H9: NO concentrations are higher in pericontusional brain following TBI.
Based on the current evidence this hypothesis is rejected.
• H10: NO is correlated with energy metabolites in both pericontusional and radiologically
normal brain.
Based on the current evidence this hypothesis is accepted.
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Chapter 8
Study VI - Characterising the
Dynamics of Cerebral Metabolism
following Traumatic Brain Injury
8.1 Introduction
Cerebral metabolic dysfunction has been described in acute brain injury of various aetiology, in-
cluding TBI, ischaemic stroke, and intracerebral haemorrhage, and has an important role in poten-
tiating secondary injury cascades such as the induction of pro-inflammatory cytokine signalling
and microvascular breakdown causing blood brain barrier permeability [111, 167]. Various states
of metabolic dysfunction have been hypothesised and demonstrated from evidence accrued in cell
culture and tissue models and from animal and human studies. Broadly, these can be classified
as cellular substrate deficiency (as a consequence of tissue ischaemia or local diffusion barriers),
aerobic glycolysis, or, lastly, a failure of oxidative phosphorylation that has been dubbed ’mito-
chondrial dysfunction’ [27]. Distinguishing between these dynamic states within individual TBI
patients in vivo is important for tailoring appropriate therapeutic interventions in an attempt to
ameliorate the extent of secondary injury and improve neurological outcome.
Cerebral microdialysis is an invasive neuromonitoring technique that permits continuous real-
time sampling of brain extracellular fluid and assessment of cerebral metabolism in the intensive
care unit [79]. Standard metabolites assayed on bedside analyzers include glucose, lactate, pyru-
vate, glutamate, and glycerol. There is a body of observational evidence to support absolute
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values, ratios, and temporal trends of specific metabolites as indicators of cerebral metabolic dys-
function. The most extensively studied parameter is the lactate/pyruvate ratio (LPR), generally
accepted to be an index of cellular redox state and the balance between oxidative and anaerobic
metabolism. Patients with average or prolonged LPR above thresholds of 25 or 40 are more likely
to die or have unfavourable outcome following TBI [79]. Low cerebral glucose has similarly been
associated with worse outcome both in observational series and interventional studies compar-
ing alternative glycaemic control regimens [79]. Identically LPR values can potentially result from
an infinite range of combinations of absolute lactate and pyruvate concentrations wherein one or
both may be higher or lower than their respective normal range. Similar increases in LPR resulting
from very different changes in lactate and/or pyruvate will likely reflect distinct states of energy
compromise, for instance ischaemia or subtrate deficiency as opposed to aerobic hyperglycolysis
[185, 21]. Thus, there as been much recent work on defining classifications of lactate, pyruvate,
and LPR values that are proposed to map to various metabolic states. A further aspect crucial to
interpreting glucose, pyruvate, and lactate concentrations, and their trends in vivo, is that they
are not independent variables and display strong covariance, a fact that is often overlooked or
not explicitly addressed in the microdialysis literature [123]. Characterising the functional form
of the relationships between these metabolites is fundamental to understanding how they change
in concert and in forecasting the response to therapeutic interventions.
Glycolysis is a series of enzymatic reactions, some of which are irreversible, and the detailed
kinetics and metabolic control of the pathway are complex. However, the overall rate of gly-
colysis can be well approximated as a single-step irreversible reaction with Michaelis-Menten
kinetics[124], i.e.:
Jgly =
VMaxgly · Gc
KMgly + Gc
(8.1)
where Jgly is the rate of glycolysis, VMaxgly is the (asymptotic) maximal rate, Gc is the cytosolic
glucose concentration, and KMgly is the Michaelis rate constant. This implies that the rate of pro-
duction and concentrations of the end products of glycolysis, including pyruvate, should exhibit
a saturable increasing relationship with glucose concentrations. Lactate dehydrogenase (LDH) is
the cytosolic enzyme that regulates the balance of the reversible interconversion of pyruvate and
lactate together with NAD and NADH. A suitable rate equation for LDH is [152]:
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Jldh =
VMax
F
ldh
(
Pc · NADHc
KMFldh
)
−VMaxRldh
(
Lc · NADc
KMRldh
)
1 +
(
Pc · NADHc
KMFldh
)
−
(
Lc · NADc
KMRldh
) (8.2)
where Jldh is the directional reaction rate, VMax
F
ldh and V
MaxR
ldh are the maximal forward and
reverse reaction rates, KM
F
ldh and K
MR
ldh are the respective rate constants, and Pc, Lc, NADc, and
NADHc are the concentrations of pyruvate, lactate, NAD, and NADH, respectively. Assuming a
steady-state reaction rate, rearrangement of this equation demonstrates that pyruvate and lactate
concentrations should be linearly related. These rate equations therefore suggest hypothetical re-
lationships between the metabolic parameters obtained with microdialysis that can be tested in
TBI patients. Importantly, although microdialysis samples the extracellular concentrations, both
glucose transport via the GLUT family of transporters (predominantly GLUT1), and pyruvate and
lactate transport via monocarboxylate transporters (MCT) display linear relationships between
extracellular and intracellular concentrations of the respective metabolites [61, 152]. Therefore,
the functional form (i.e. linear, hyperbolic, etc) of the relationships between the extracellular con-
centrations of glucose, pyruvate, and lactate would be expected to mimic those of the intracellular
compartment, albeit with different parameterisation.
In this study we have utilised microdialysis data from a large cohort of TBI patients with four
principal objectives. Firstly, to quantify the independent effect of LPR and cerebral glucose on
neurological outcome; secondly, to characterise the temporal course of metabolites following TBI;
thirdly, to assess the functional relationships between metabolites and other monitoring variables,
such as CPP; and finally to examine the functional inter-relationships of the key energy metabo-
lites glucose, pyruvate, and lactate.
8.2 Methods
8.2.1 Patients
This is an observational study of 619 adult (>16 years) patients with TBI admitted for management
on the neurocritical care unit (NCCU) at Addenbrooke’s Hospital, Cambridge, UK over twenty
years from 1997 to 2016. Data from the initial 223 patients in this cohort have been reported pre-
viously [172, 173].
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All patients required intubation and mechanical ventilation and were managed according to a
typical standardised tiered therapy protocol for TBI patients (Supplemental information). In
brief, patients were sedated, paralysed, and mechanically ventilated to a target PaCO2 of 4.5-5
kPa. Vasopressors are used to maintain a cerebral perfusion pressure (CPP) of 55-65mmHg. In re-
sponse to elevated intracranial pressure there was a staged application of osmotherapy, external
ventricular drainage, barbiturate coma, and ultimately decompressive craniectomy. Six month
neurological outcome was assessed with the Glasgow Outcome Score, which was dichotomised
into favourable (GOS 4-5) and unfavourable outcome (GOS 1-3) as appropriate.
8.2.2 Monitoring
Routine invasive neuromonitoring comprised of a triple lumen cranial access device (Technicam,
Newton Abbott, UK) placed by default in the right frontal region unless contraindicated. An in-
tracranial pressure (ICP) monitor (Codman, Raynham, MA, USA), a brain tissue oxygen (PbtO2)
probe (Licox Neurosciences, Andover, UK), and a microdialysis catheter (CMA 71, CMA/Mdialysis
AB, Stockholm, Sweden; 100kDA molecular weight cut-off) were introduced via the access device
and position with their tips in the white matter. Catheter location was confirmed on subsequent
computed tomography and classified as pericontusional or within radiologically ’normal’ brain
based on their proximity to traumatic lesions.
Microdialysis catheters were perfused with standard crystalloid perfusate (CMA/MDialysis AB,
Stockholm, Sweden) at 0.3µ l/min. Vials containing dialysate were changed at regular intervals
as close to hourly as practicable and assayed on bedside analysers (CMA 600 and ISCUS models;
CMA/Mdialysis AB, Stockholm, Sweden) for concentrations of lactate, pyruvate, glucose, gluta-
mate, and glycerol.
Arterial blood pressure (ABP) was monitored continuously via a peripheral intra-arterial catheter.
ICP, ABP, and PbtO2 were digitised and recorded at 50-200Hz using ICM+ software (ICM+, Cam-
bridge Enterprise/University of Cambridge, UK). In addition to storing the raw signals ICM+
has the facility for online calculation of secondary indices including the PRx metric of cerebral
autoregulation. This is quantified as the Pearson correlation coefficient between thirty mean val-
ues of ICP and ABP calculated over 10 second windows [40]. A positive PRx value suggests ICP
changing in concert with ABP, indicative of poor or absent autoregulation; PRx of approximately
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zero or negative indicates intact autoregulation [40].
8.2.3 Data Processing
The raw data files from the microdialysis analysers were parsed and imported using custom
scripts. Where the analyte is below the lower limit of detection of the assay and/or there is
insufficient dialysate in a vial the datum is flagged as erroneous and these were excluded. As a
further check the collated data were filtered of any values below the lower limits of detection of
the analysers specified in the manufactuere’s manual: glucose 0.1 mM, lactate 0.1mM, pyruvate
10 microM, glutamate 1 mM, glycerol 10 mM. To combine the high frequency ICP, CPP, PRx, and
PbtO2 signals with microdialysis data the former were exported in minute-by-minute format and
then combined in epochs corresponding to the times of the sequential microdialysis assays and
accounting for the 17 minute period that fluid takes to leave the semipermeable section of the
microdialysis catheter and reach the collection vial.
To mitigate the effect of a small proportion extreme outliers when calculating summary statis-
tics the data were Winsorized at the 0.00125 quantile, i.e. data that were either above or below the
99.875th and 0.125th quantile, respectively, were changed to be equal to the respective quantile
threshold. This process does not remove data (compared with, for example, trimming) but allows
more robust calculation of parametric statistics.
8.2.4 Statistical Analysis
All statistical analysis was performed in R (v.3.4.3; www.r-project.org) using the packages: nlme,
rms, mgcv, qgam, lattice, mice. Ordinal proportional hazards regression was performed with the lrm
function from the rms package. Due to the nature of the cohort a substantial proportion of patients
had at least one missing data point which would result in exclusion from cohort-level regression
and a potential source of bias. Therefore for these analysis the missing data were multiple im-
puted using the fully conditional chained equation model available in the mice R package.[180].
Missing data were treated as missing completely at random (MCAR) as the absence of data log-
ging or recordings not being available for analysis was assumed not to be related to patients’
prognosis or outcome. Continuous variables were imputed with predictive mean matching, and
factors with logistic regression. Each of ten imputed datasets were then each entered into the re-
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gression model(s) and the results pooled to obtain overall estimates of coefficients and standard
errors.
For analysis of the hourly data linear mixed-effects (LME) and generalised additive mixed mod-
els (GAMM) were used.[199] The latter of these is an extension to the mixed modelling frame-
work to include non-linear smooth functions of the independent variables being studied, repre-
sented in a choice of spline basis functions, in addition to categorical and/or linear (parametric)
terms. This allows data-driven estimation of non-parametric non-linear relationships between
variables. Whereas including polynomial or spline terms within standard least-squares regres-
sion or mixed-models is possible, these have a fixed degree of freedom and there is a tendency
to overfit noise within the data. In the GAM(M) framework the degrees of freedom which deter-
mine the non-linearity or ’wiggliness’ of the smooth terms is included as part of the model-fitting
process by (restricted) maximum likelihood estimation and can be reduced to the null space of
linear terms if that is all that is supported by the data. Furthermore, patient-level random effects
and autoregressive error terms can also be included and they are therefore well served to analyse
time-series/longitudinal data of differing duration from multiple individuals. For all analyses,
unless otherwise stated, the basis for smooth terms was a cubic regression spline with ten knots.
Random effects for each patient together with a first order autoregressive term (AR1) using the
gamm and emphbam functions from the mgcv package was used with Restricted Maximum Likeli-
hood (REML) as the fitting method. To evaluate smooth quantile relationships between variables
the qgam package was used which extends the the mgcv GAM framework to include quantile
regression[49].
8.3 Results
8.3.1 Demographics
Data for a total of 619 patients were collated for the study; baseline characteristics are summarised
in Table 8.1. GCS and pupillary reaction at initial presentation were not available from electronic
records for 42 (6.7%) and 112 (18.7%) of patients, respectively. Outcome could not be determined
in 37 (6.0%) of patients. The median time to the initiation of microdialysis monitoring was 26.9
[16.5-50.1] hours and was continued for a median IQR] of 4.8 [2.7-7.8] days. In total there were
56,307 microdialysis epochs included, with a median sampling interval of 1.02[1.00-1.40] hours. In
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addition to microdialysis, 461 (74.5%) patients had ICM+ data recording (the remaining patients
would also have had ICP and PbtO2 monitoring as standard clinical care, but high resolution data
were not recorded for offline analysis).
Characteristic Total N = 619
Age (median [IQR] years)
37 [24-52]
Sex (N [%])
Male 472 [76.3]
Female 147 [23.7]
GCS (N [%])
3-8 387 [62.5]
9-12 104 [16.8]
13-15 86 [13.9]
N.A. 42 [6.7]
Pupils (N [%])
Both reactive 417 [67.4]
Unilateral unreactive 69 [11.1]
Bilateral unreactive 21 [3.4]
N.A. 112 [18.1]
Marshall CT Score (N [%])
Class II 298 [48.1]
Class III 92 [14.9]
Class IV 21 [3.4]
Class V 96 [15.5]
Class VI 36 [5.8]
N.A. 76 [12.3]
Mechanism of Injury (N [%])
Assault 53 [8.6]
Fall 200 [32.3]
Cyclist 37 [6.0]
Pedestrian RTA 51 [8.2]
Occupant RTA 260 [44.9]
Other and N.A. 18 [2.9]
Table 8.1: Admission baseline characteristics of the patient cohort.
IQR, interquartile range; GCS, Glasgow Coma Scale; CT, computed tomorgraphy; N.A., not available.
8.3.2 Lactate/Pyruvate Ratio and Outcome
Univariate comparison of individual mean LPR was not significantly different between unfavourable
and favourable outcome groups when averaged over the first 24h from injury but was signifi-
cantly different at 72h from injury (Figure 8.1 median [IQR]: 25.8 [11.0] vs. 24.2 [0.6], p=0.023) and
significantly higher proportion of time at LPR>25 (median [IQR]: 50.6% [90.0] vs 29.8% [79.0],
p=0.047). When averaged over the whole monitoring period there was again no significant dif-
ference between groups.
To examine the independent effect of LPR on outcome a proportional odds logistic regression
of the five point GOS outcome scale against age, presenting GCS, pupillary reaction, Marshall
CT score, and <24h to <168h mean values of glucose, LPR, ICP, CPP, PRx, and PbtO2 was con-
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ducted. Tenfold multiple imputation of missing data using chained equations was performed
and the proportional odds regression repeated and pooled; the results are shown in Table 8.2.
Outcome was missing for 37 (6.0%) patients. Among the independent predictor variables there
was 22-27% missing values depending on the time period over which the physiological data were
averaged. At all time points age, low GCS (<9), bilaterally unreactive pupils, and unevacuated
mass lesion were significant predictors of outcome. Of the monitored variables, ICP, PRx, and
LPR were significant predictors when averaged over 72h or longer. Cerebral glucose was also
significantly associated with outcome when averaged over the first seven days from injury. As
expected, the overall predictive power of the regression improved with time as evidenced by the
increase in Harrell’s C-statistic, equivalent to area under the receiver operating curve for binary
logistic regression.
≤24h ≤72h ≤120h ≤168h All
Age −0.032 (0.006)∗∗∗ −0.033 (0.005)∗∗∗ −0.031 (0.005)∗∗∗ −0.031 (0.005)∗∗∗ −0.031 (0.005)∗∗∗
GCS 9-12 −0.221 (0.294) −0.168 (0.275) −0.163 (0.274) −0.157 (0.280) −0.171 (0.285)
GCS ≤ 8 −0.707 (0.246)∗∗ −0.692 (0.227)∗∗ −0.708 (0.229)∗∗ −0.688 (0.236)∗∗ −0.726 (0.238)∗∗
Pupils (Unilateral) −0.410 (0.271) −0.461 (0.301) −0.459 (0.290) −0.454 (0.288) −0.444 (0.282)
Pupils (Bilateral) −1.728 (0.435)∗∗∗ −1.791 (0.408)∗∗∗ −1.712 (0.404)∗∗∗ −1.661 (0.405)∗∗∗ −1.623 (0.410)∗∗∗
Marshall III −0.314 (0.275) −0.210 (0.254) −0.260 (0.258) −0.254 (0.262) −0.248 (0.279)
Marshall IV −0.638 (0.409) −0.429 (0.460) −0.404 (0.455) −0.365 (0.456) −0.339 (0.455)
Marshall V 0.029 (0.224) −0.057 (0.214) −0.088 (0.208) −0.095 (0.210) −0.117 (0.210)
Marshall VI −1.015 (0.326)∗∗ −0.893 (0.342)∗∗ −0.814 (0.345)∗ −0.876 (0.340)∗ −0.854 (0.346)∗
Glucose −0.026 (0.074) −0.082 (0.077) −0.113 (0.071) −0.147 (0.070)∗ −0.186 (0.073)∗
LPR −0.006 (0.006) −0.012 (0.006)∗ −0.015 (0.007)∗ −0.016 (0.007)∗ −0.014 (0.007)∗
Glutamate −0.002 (0.003) −0.004 (0.005) −0.001 (0.005) −0.002 (0.005) −0.001 (0.005)
Glycerol −0.000 (0.001) −0.000 (0.001) 0.001 (0.001) 0.001 (0.001) 0.000 (0.001)
ICP 0.003 (0.028) −0.061 (0.019)∗∗ −0.057 (0.017)∗∗∗ −0.064 (0.019)∗∗∗ −0.078 (0.020)∗∗∗
CPP −0.001 (0.024) −0.008 (0.012) −0.002 (0.014) 0.000 (0.013) 0.009 (0.014)
PRx −0.032 (0.574) −1.668 (0.579)∗∗ −1.921 (0.572)∗∗∗ −2.215 (0.591)∗∗∗ −2.602 (0.649)∗∗∗
PbtO2 0.003 (0.010) 0.008 (0.008) 0.008 (0.008) 0.006 (0.007) 0.003 (0.008)
C (AUROC) 0.681 0.694 0.695 0.701 0.709
∗∗∗p < 0.001, ∗∗p < 0.01, ∗p < 0.05
Table 8.2: Proportional odds regression against Glasgow Outcome Score (GOS) of baseline characteristics and monitor-
ing data averaged over different intervals following injury. Numbers are regression coefficients with standard
errors in parentheses; statistical significance indicated by asterix. Harrell’s C statistic, equivalent to the area
under the receiver operating curve (AUROC) is also included for each model.
GCS, Glasgow Coma Scale; LPR, lactate/pyruvate Ratio; ICP, intracranial pressure; CPP, cerebral perfusion
pressure; PRx, measure of autoregulation (see text); PbtO2, brain tissue oxygen tension.
8.3.3 Metabolism in Pericontusional Brain
Patients’ CT scans, where available, were examined and microdialysis catheter location cate-
gorised as pericontusional if within 1cm of haemorrhage or pericontusional oedema. Overall,
catheter location was determined to be pericontusional in 110 patients and in radiologically nor-
mal brain remote from obvious injury in 330. The remaining 179 patients did not have CT scans
demonstrating catheter position. Mean LPR over the first 72h from injury was significantly higher
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in pericontusional brain (29.1 vs 25.1, p=0.0038). There was no significant difference in glucose
(1.84 vs 1.75, p=0.603)
8.3.4 Temporal trends
Generalized additive mixed models, including per-patient random effects and first-order autore-
gressive terms, were generated to fit data over first temporal profile of microdialysis analytes 14
days following injury. To ensure sufficient degrees of freedom to accurately reflect the temporal
trends the smooth terms utilised a 14-knot cubic regression splines. Figure 8.2 shows the tempo-
ral profile of the monitored variables split by favourable and unfavourable outcome categories.
Figure 8.3 demonstrates that, as expected, the data are highly autocorrelated and that the fitting a
GAMM model including an AR1 term accounts for most of the autocorrelation in the residuals.
LPR showed an initial decreasing trend over the first c.48h and then generally increased to day
14; there were significant changes over time for both favourable (F7.80=24.02 p<2e-16) and un-
favourable (F9.88=7.61 p=1.5e-10) outcome groups but with significant differences in both overall
mean intercept (4.62 [1.38], T=3.35, p=0.00081) and trend between groups (F2.16=3.94 p=0.015)
was significantly different in the unfavourable outcome group, both in terms of mean value (2.52
[0.50]mM, t=5.02 p=5.1e-07) and temporal trend (F=18.04 p=2.16e-05); overall, LPR was on aver-
age higher in the unfavourable group until around day 10 following injury. Pyruvate exhibited a
significant, and generally increasing, temporal trend (F4.39=4.42 p=0.0011) but this did not differ
significantly either in mean value or trend between outcome categories. Of interest, cerebral glu-
cose was significantly lower over days five to eleven following injury in the favourable outcome
group. Both glutamate and glycerol were generally higher in the unfavourable outcome group
but not significantly different. The trends in mean intracranial pressure and PRx were signifi-
cantly different between outcome groups throughout virtually the entire 14 day period, whereas
the confidence intervals for CPP overlapped indicating no significant difference. PbtO2 was simi-
lar between groups in the the first week after injury but then was lower in the those patients who
ultimately had an unfavourable outcome.
8.3.5 Relationship between LPR and CPP, PRx, and PbtO2
To assess the associations between CPP, PRx, and PBtO2 and cerebral metabolism a further se-
ries of GAMMs were generated with LPR as the dependent variable, again including random
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Figure 8.2: Fitted population mean time courses for microdialysis analytes using generalised additive mixed models, by
dichomtomised Glasgow Outcome Score group.
Lactate (A), Pyurvate (B), Lactate-Pyruvate Ratio (LPR, C), Glucose (D), Glutamate (E), and Glycerol (F).
Shaded areas indicated 95% intervals.
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Figure 8.3: Autocorrelogram plots for the GAM model of LPR over time, A without including an AR1 autoregressive term
and B including the autoregressive term (phi = 0.57). Strong autocorrelation in the residuals of the time series
is evident and this is largely removed when the model includes the AR1 term.
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effects and first-order autoregressive terms. All relationships were non-linear (Figure 8.4). In-
spection of the GAMM models suggested thresholds of CPP below 60mmHg (2.21% of samples),
PRx above 0.2 (24.21% of samples), and PBtO2 below 20mmHg (29.26% of samples) were asso-
ciated with increased LPR, although the confidence interval was wide and included zero effect
for PbtO2. Dichotomising the data based on these thresholds found significant differences in LPR
with Wilcoxon tests (all p<1e-10). Comparison of the dichotomised groups with mixed models
incorporating patient random-effects and autoregressive errors found significantly lower LPR for
CPP >60mmHg (-1.42, t=-2.78, p=0.0055) and for PRx <0.2 (-0.80, t=4.27, p<1e-6), with borderline
effect of PbtO2 >20mmHg(-0.61, t=-1.91, p=0.056). Dichotomising PbtO2 at a lower threshold of
10mmHg (7.04% of samples) did not find a significant difference.
8.3.6 Glucose and LPR
Figure 8.5 shows the nonlinear relationship between cerebral glucose concentration and LPR,
demonstrating that LPR rapidly increases as glucose concentrations reduce below approximately
2mM; the confidence intervals are narrow indicating this was a robust feature amongst the pa-
tients in the cohort. Figure 8.6A shows the fitted GAMMs between lactate, pyruvate and glucose.
Although low glucose was associated with a high LPR the absolute concentrations of lactate and
pyruvate varied positively with glucose in an approximately hyperbolic pattern, as hypothesised.
To confirm this relationship a double-reciprocal plot (Figure 8.6B) was examined as this should
show a linear relationship, and indeed this was the case. Figure 8.6C shows the GAMM model be-
tween lactate and pyruvate and confirms the essentially linear relationship, as predicted by LDH
rate equation. To test whether this finding was representative the pyruvate-lactate correlation
was estimated for each individual patient (Figure 8.6D). Both Pearson and Spearman correla-
tion coefficients were calculated; the former is a measure of linear association and the latter is
additionally sensitive to non-linear monotonic associations. Correlation coefficient values were
generally high (i.e. 0.8) and the distribution was similar with both coefficients lending weight
to the contention that assumption of a linear trend was most appropriate. Lastly, a linear mixed
model between lactate and pyruvate including random intercept and slope terms together with
a first-order autoregressive term. Figure 8.6E displays the variation in the slope and intercept of
the pyruvate-lactate relationship across patients in the cohort.
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Figure 8.5: (top) density histogram indicating the distribution of cerebral glucose; (middle) bivariate scatter plot of glucose
with LPR overlaid with 10th, 25th, 50th (median), 75th and 90th fitted quantiles (dashed lines); (bottom) mean
trend from GAMM model with shaded 95% confidence interval.
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Figure 8.6: Inter-relationships between glucose, pyruvate, and lactate. A: GAMM model of microdialysis glucose and
pyruvate. B: Double reciprocal GAMM model of glucose and pyruvate. C: GAMM model of pyruvate and
lactate concentrations. D: Kernel density distribution estimate of Pearson (blue) and Spearman (green) corre-
lation estimates for pyruvate-lactate association within each subject. E: linear mixed effect model of pyruvate
and lactate with overall fixed effect (blue) and individual trends including the random effects for intercept and
slope (gray lines). Red dashed line indicates reference line along which LPR=25. Shaded regions indicate
95% confidence intervals for all panels.
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Figure 8.7: Bivariate plot of lactate and pyruvate colour coded by cerebral glucose concentration (colorbar, [mM]). Refer-
ence lines for LPR=25 and LPR=40 are overlaid.
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8.3.7 Classifying metabolic dysfunction
Examination of the raw data in a bivariate plot of pyruvate and lactate suggests a potential
classification of metabolic states based on LPR and glucose (Figure 8.7). The ’normal’ state of
LPR<25 and normal glucose concentrations (>1mM) is considered Type I. Type II is the situation
of LPR<25 with glucose <1mM and Type III that of elevated LPR>25 and adequate cerebral glu-
cose >1mM. Finally Type IV represents the most severely deranged state with both LPR>25 and
glucose <1mM. The four metabolic states were then compared for differences in other microdial-
ysis and neuromonitoring variables with a linear mixed model incorporating post-hoc pairwise
comparisons between groups and a Bonferroni correction of the p-values (Figure 8.8). Glutamate
was significantly higher in both Type I and III, corresponding with higher glucose. PRx was sig-
nificantly impaired (i.e. worse autoregulation) and ICP higher during periods of Type III and IV
metabolism. CPP and PbtO2 was not different between any of the classes.
8.4 Discussion
8.4.1 Cerebral Metabolism and Outcome
This study of combined microdialysis and neuromonitoring data in 619 TBI patients represents
the largest series in the literature and builds on the evidence from previous studies, including the
findings from the initial 223 patients in the cohort [172]. Cerebral LPR averaged per patient over
the first three, five, or seven days following injury was found to be independently associated with
neurological condition at six months following injury, measured ordinally on the GOS scale. This
affirms findings in previous studies [79]. The lack of association between LPR and outcome when
averaged over the first 24 hours or the whole period of monitoring likely reflects the relative lack
of data in the early period following injury and the confounding factors and selection bias in pa-
tients who where monitoring beyond seven days. It should be emphasised that the modelling
presented here is not intended to motivate adoption of LPR (or any other microdialysis-derived
parameter) as a specific or precise prognostic marker in the clinical management of individual
TBI patients. Rather, the rationale for examining the association with outcome is to test the broad
face-validity of the presumption that derangements of cerebral metabolism are related to out-
come after TBI (and brain injury in general) and the corollary that therapy directed at normalising
metabolism may have potential benefit.
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Figure 8.8: Marginal means and 95% confidence intervals for microdialysis and neuromonitoring variable between the
four metabolic states. Type I: LPR<25, glucose >1mM; Type II: LPR<25, glucose <1mM; Type III: LPR>25,
glucose >1mM; Type IV: LPR>25, glucose <1mM. Bars indicate significant pairwise comparisons: ***p<0.001,
**p<0.01, *p<0.05; all Bonferroni corrected for multiple comparisons.
Consistent with the regression analysis, the mean temporal course of LPR was significantly differ-
ent over the first several days from injury between dichotomised outcome groups. Both groups
exhibited a decrease in LPR over the initial 48 hours following injury, possibly consistent with re-
covery from any acute derangements of ICP and cerebral blood flow together with physiological
stabilisation in the intensive care unit [1]. Thereafter LPR increased, with a more pronounced and
variable pattern in poor outcome patients. At a mean level, the secondary increase in LPR was due
primarily to increasing lactate, whereas the trend for pyruvate was relatively flat. Impaired au-
toregulation (PRx >0.2), was strongly associated with increased LPR, suggesting techniques such
as targeting ’optimal CPP’ may be of substantial benefit in normalising metabolic derangements
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following TBI [8]. Low CPP (<60mmHg) was also associated with raised LPR but the incidence of
CPP below this threshold was very low. Somewhat surprisingly, the relationship between PbtO2
and LPR was weak, with only a non-significant trend towards higher LPR at low brain oxygen
tensions. Fewer patients in the cohort had brain tissue oxygen recordings compared with ICP and
CPP, which may in part explain the lack of observed association.
8.4.2 Metabolic Dysfunction following TBI
The canonical model of cellular respiration commences with glucose entering the cytosol, pro-
ceeding along the series of enzymes of the glycolytic pathway to pyruvate (with net gain of two
ATP molecules), which in turn enters the mitochondrion to feed the TCA cycle and the electron
transport chain, producing a further 34 molecules of ATP. When oxygen is insufficient, pyruvate
is converted to lactate to regenerate NAD and allow anaerobic glycolysis to continue. In the
CNS there is evidence that glia and neurons are metabolically coupled in the so-called ’Astrocyte-
Neuron Lactate Shuttle’ (ANLS) [19, 130]. This model posits that neurons do not generally utilise
glucose directly but predominantly generate pyruvate from lactate that is produced by glycolysis
in astrocytes. During periods of greater neuronal activity and metabolic demand synaptic gluta-
mate release increases, which is in turn taken up into surrounding astrocytes and upregulates gly-
colysis to generate further lactate that diffuses to neurons for utilisation in oxidative metabolism.
Several compelling lines of evidence support the ANLS in animal models and humans but irre-
spective of the more complex arrangements, net brain metabolism remains predominantly oxida-
tive in normal circumstances. As evidenced in the present study, frank cerebral ischaemia - i.e.
low cerebral perfusion pressure and/or tissue hypoxia - is uncommon with modern critical care
management of arterial blood pressure, intracranial pressure, and ventilation. Nonetheless, accu-
mulated evidence suggests a number of other forms of metabolic dysfunction commonly manifest
after TBI, and different types may coexist dynamically or be regionally localised within an indi-
vidual patient [27, 26, 83]. Even if cerebral blood flow is adequate, substrate delivery may be
impaired by local diffusion barriers that result from cell necrosis and matrix breakdown. Aerobic
hyperglycolysis, wherein anaerobic glycolysis is upregulated despite sufficient oxygen availabil-
ity, has been demonstrated to be a common early phenomenon in both preclinical models and
human TBI patients [21]. Overlapping to some extent is the concept of ’mitochondrial dysfunc-
tion’, a situation where oxidative respiration cannot proceed effectively due to deficiencies in the
TCA cycle or electron transport chain, with an obligate increase in the rate of glycolysis to main-
tain ATP production.
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Characterising the monitoring ’signature’ of distinct aetiologies of metabolic dysfunction follow-
ing TBI is a major goal of investigation and a key step in testing potential therapeutic strategies
is reliable identification of the underlying pathophysiological state. Previously, LPR elevations
have been loosely categorised as ischaemic/Type 1, corresponding with high lactate and normal
or low pyruvate, and non-ischaemic/Type 2 reflecting normal lactate with low pyruvate. The
latter of these states is suggested to reflect states of hyperglycolysis with excess substrate de-
mand [101, 43]. The present study has shown that, within individuals, there is a strong linear
relationship between pyruvate and lactate concentrations, and thus both change in concert. This
association was demonstrated with flexible generalised additive mixed models, which do not
impose a pre-determined functional form on the relationship between dependent and indepen-
dent variables, and are able to account for the strong autocorrelation in biological time series that
would otherwise risk overfitting. The parameters of the linear pyruvate-lactate relationship (i.e.
the gradient coefficient) and hence the relative magnitude of changes in each metabolite was vari-
able between patients. A key point to emphasise is that although lactate and pyruvate follow a
linear relationship, if this is parameterised by a non-zero intercept then the LPR will change as the
metabolite concentrations change. More precisely: if the equation of a straight line is y = ax + b
and |b| > 0, the ratio of variables will be y/x = a+ b/x and thus the ratio is nonlinearly dependent
on the concentration. Only in the circumstance of an exactly zero intercept will the quotient of
linearly-dependent variables remain constant (equal to the gradient m). Glucose was confirmed
to have a strong nonlinear association with the concentration of pyruvate (and hence lactate),
with features consistent with standard saturable Michaelis-Menten kinetics. As further evidence
of this the relationship was linearised by examining a model of reciprocal concentrations of glu-
cose and pyruvate. This is akin to a Lineweaver-Burke plot employed to estimate rate constants
and maximal velocities of in enzyme kinetics [39]. Here the double reciprocal plot was used sim-
ply to characterise the functional relationship; parameters estimated from the plot are not readily
interpretable, although may serve as a way of statistically comparing patient groups. Several fur-
ther questions regarding the relationships between glucose, pyruvate, and lactate remain to be
examined in further studies. For instance: do the parameters of the functional relationships differ
significantly across the spectrum of TBI (i.e. diffuse vs focal) and is there regional heterogeneity
within individual patients? Do the parameters follow a predictable temporal course following
injury and does this differ between patients with favourable and unfavourable outcome?
Overall, these empirical findings of this study show that as glucose decreases, both pyruvate and
lactate decrease, and LPR rises. Pyruvate, Lactate, and LPR exhibited most rapid rate of change
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at glucose concentrations of approximately 1mM. Although cerebral metabolic derangement is
likely a continuum of both type and degree, the present findings motivated an alternative clas-
sification of four metabolic states based on a threshold LPR of 25 and cerebral glucose of 1mM.
Examining the mean lactate and pyruvate concentrations in the four classes, the group defined
here as Type III would largely correspond with the previously defined ’ischaemic’ or Type 1 LPR
elevation, and the current Type IV would be defined as non-ischaemic/Type 2. The findings of no
significant difference in CPP or PBtO2 speak against frank cerebral ischaemia in either group but
PRx was significantly higher in both Type III and Type IV classes, suggesting a possible mismatch
in substrate demand and supply.
These results implicate glucose concentration as a key indicator or determinant of cerebral metabolic
state, together with LPR. The natural question that follows is whether supplementing cerebral
glucose improves LPR and has a beneficial effect on patient outcome. Target ranges for plasma
glucose in the neurointensive care unit are a subject of much debate and several studies have
shown that tight control with continuous insulin infusions, as used in general intensive care, have
been associated with reduced cerebral glucose and elevated LPR in TBI patients when compared
with more permissive glycaemic control[184, 132, 125]. However, early hyperglycaemia in TBI
patients is associated with poor outcome [99] and intravenous glucose supplementation has not
shown consistent benefit in TBI models [118, 33]. Thus, the role of active glucose administration
in TBI patients remains an area for future study. Defining the parameters of individual patients’
linear pyruvate-lactate relationship does potentially provide an indication of the likely cerebral
metabolic response to additional glucose. For example, the subgroup of patients with a gradient
>25 would be expected to have worsening of their LPR in response to increased pyruvate and
lactate, whereas patients with a gradient <25 would be predicted to show improvement. This
supposes that the linear pyruvate-lactate relationship is not altered by intervention, which is a
further point that remains to be tested in future investigation.
8.4.3 Limitations
This study has a number of limitations inherent to observational investigations. Missing data
was addressed with multiple imputation but this is imperfect and possibility of bias remains. Al-
though the general management protocol for TBI patients at our institution is standardised, the
specific interventions and their timing for each patient was not recorded and therefore potential
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confounding effects on the data are not quantifiable. However, this is in part mitigated by the
large number of patients included. Despite the strong associations between variables observed,
extrapolation to the effects of manipulating, for example, glucose concentrations, are only hypo-
thetical and speculative; further interventional studies are required.
8.5 Summary and Context
Cerebral metabolic dysfunction, as evidenced by raised LPR, is associated with patients’ neuro-
logical outcome following TBI. Low CPP and PbtO2 should be avoided as per current guidelines.
Targeting CPP to minimise PRx (i.e. optimise autoregulation) may be beneficial in ameliorat-
ing metabolic dysfunction. The relationship between brain lactate and pyruvate is linear, with
variable parameters between individual patients. Glucose is strongly related to both lactate and
pyruvate concentrations and LPR; the benefit of supplementing glucose in patients with raised
LPR and a favourable lactate-pyruvate relationship warrants further research.
8.5.1 Hypotheses
• H11: Cerebral metabolic parameters predict neurological outcome following TBI
Based on the current evidence this hypothesis is accepted.
• H12: Derangements in LPR and cerebral glucose are different in radiologically normal and
contused brain following TBI.
Based on the current evidence this hypothesis is partially accepted.
• H13: There are defined functional relationships between the principal energy molecules
assayed with microdialysis, namely glucose, pyruvate, and lactate.
Based on the current evidence this hypothesis is accepted
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Chapter 9
Summary and Future Directions
9.1 General summary
The overarching aim of this thesis was to detect BBB permeability in relation to brain contusions,
characterise the temporal course of expansion and progression of contusions and associated brain
oedema, and to identify signalling mediators and metabolic derangements in pericontusional
brain that may be contributors to this process.
A robust and simple stereological technique for measuring contusion volume was validated and
utilised in fifty-two patients to demonstrate that the majority of contusion expansion occurs
within the first 72h of injury. The degree of contusion expansion was associated with severity
of metabolic derangment measured by LPR.
Dynamic contrast enhanced perfusion CT imaging did not show evidence of BBB permeability
in ten TBI patients imaged with a total of 16 scans. A number of possibilities may explain this
finding but the utility of DCE-CT assessment of BBB dysfunction in the context of brain trauma
remains unclear.
Using microdialysis catheters targeted to the vicinity of contusiuons and concomitantly placed
in non-injured brain in twelve TBI patients, a spatially segregated pro-inflammatory pattern of
cytokine production was observed in pericontusional brain that was most prominent within a
similar time period from injury. Additionally, chemokines promoting cellular infiltration and
matrix metalloproteinases with known activity against endothelial tight junctions were also pref-
erentially expressed in pericontusional brain within the initial three days from injury. There was
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some evidence for a correlation between MMP-9 expression and contusion expansion.
In a large cohort of over six hundred TBI patients managed with microdialysis, the associations
between energy molecules and physiological parameters including ICP, CPP, PRx, and PbtO2
were explored to better characterise their functional relationships. Non-linear associations be-
tween the principal measure of metabolic stress, namely LPR, and brain glucose, CPP, PRx, and
oxygenation were identified. Glucose and PRx emerged as having the strongest association with
LPR, suggesting that interventions to optimise these parameters may have the greatest likelihood
of normalising deranged metabolism in the injured brain.
Put together, this work provides evidence for a localised pro-inflammatory response and metabolic
derangement in peri-contusional brain, the severity of which is associated with subsequent mag-
nitude of contusion and oedema progression.
9.1.1 Imaging of BBB permeability
Dynamic contrast enhance CT imaging was unable to show evidence of BBB permeability in con-
tusional or pericontusional brain within five days from injury, despite observing clear evidence of
contusion expansion and of local expression of mediators known to be associated with BBB break-
down, such as MMP-9. As discussed in the respective chapter, it is unclear whether this negative
result implies that BBB permeability is not a feature of focal TBI in humans or if fundamentally
the the DCE-CT technique or analysis is not sufficiently sensitive to detect it. Given the abundant
evidence for BBB dysfunction in focal pre-clinical TBI models it is unlikely that this process is
entirely absent in humans, although whether it is the primary mechanism of post traumatic brain
oedema certainly is disputed [177]. On the other hand, given that DCE-CT has been shown to
detect permeability related to stroke and other pathologies it is also unlikely that it should be
unable to detect the same process in TBI [108].
Further studies with modified DCE-CT protocols (e.g. extended acquisition to improve sensi-
tivity) are required, preferably incorporating multi-modality imaging with DCE-MRI or a radio-
tracer technique such as PET for comparison. Developing a reliable CT-based methodology for
quantifying BBB permeability would not only be of great practical value in the management of
TBI patients, but would be a useful surrogate end-point for early-phase interventional studies of
therapeutic agents directed at reducing BBB permeability and brain oedema.
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9.1.2 Measuring contusion progression
Commonly employed heuristic methods for quantifying the volume of intracerebral haematomas
were shown to be progressively less accurate when the lesions being studied are increasingly
irregular in shape. An alternative technique using unbiased stereology was found to have pre-
dictable accuracy and precision and was an efficient method for characterising the evolution of
the haemorrhagic contusion and associated oedema on serial CT imaging. Consistent with clinical
experience and evidence from pre-clinical studies, the most rapid phase of contusion expansion
was in the initial 72h following injury, thereafter largely plateauing. Pericontusional tissue was
shown to have more pronounced elevation of LPR and in turn higher LPR was shown to be asso-
ciated with greater contusion expansion.
Although very simple, the stereological method is suitable for measuring volume of any type
of object on cross-sectional imaging and can be adapted to estimate surface area. Although the
systematic error associated with any grid spacing can be calculated precisely; further studies to
assess inter-rater reliability for specific applications are required, particularly when lesion borders
are ambiguous. For example, in the case of contusions that have matured over several days the
the haemorrhagic core and surrounding oedema may become indistinct. However, this is simi-
larly a difficulty that affects ABC/2 and associated methods, and more sophisticated automated
and semi-automated segmentation algorithms. A reproducible technique for measuring volume
of haemorrhage and oedema will also be an important surrogate measure of any proposed inter-
vention to reduce contusion progression.
There has been much recent interest in the application of advanced machine learning algorithms
based on deep convolution neural networks to medical imaging [150]. These techniques have
been shown to be effective at both image labelling or categorisation, and segmentation of objects,
including intracerebral haematomas and contusions [87, 5]. The main obstacles to employing this
approach more widely are, firstly, the vast numbers (tens of thousands [5]) of labelled or seg-
mented scans required for effective training. Secondly, the training process requires significant
computational power and is often relatively slow therefore comparison and testing of alternative
network architectures is time consuming. One application for an efficient manual segmentation
technique such as stereology may be to generate the datasets required for training automated ma-
chine learning algorithms.
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9.1.3 Pericontusional Inflammation and Signalling
Consistent with pre-clinical studies and human microdialysis investigations in diffuse TBI, the
present study utilised targeted microdialysis and demonstrated localised increase in pro-inflammatory
cytokines and chemokines (e.g. IL-8) and underexpression of anti-inflammtory mediators (e.g.
IL-1ra and IL-10) in peri-contusional brain. In keeping with the finding of contusion expansion
predominantly occurring during the 72h following injury, the pro-inflammatory ’signature’ was
most prominent during the same timeframe. The results implicate similar signalling cascades that
are activated in patients with diffuse injury and hence that intervention with modulators such as
recombinant IL1ra may have also have an effect in focal contusional TBI. However, although IL1ra
no doubt does modify the cerebral inflammatory response, whether this is beneficial or ultimately
deleterious to reparative processes is unclear.
This study found that there was significantly elevated localised expression of MMP-9 in peri-
contusional brain, corroborating findings from in vitro and animal models which have heavily
implicated this enzyme has having a prominent role in the proteolysis intercellular tight junc-
tions and BBB permeability. As with the pro-inflammatory cytokines, MMP-9 concentrations
were highest in the first hours of monitoring and thereafter declined. The canonical upstream
regulator of MMP-9 expression and activation is VEGF and therefore this molecule had also been
expected to have increased expression in pericontusional brain. However, the temporal profiles
of VEGF in pericontusional and radiologically normal brain were similar during the initial 72h
following injury and thereafter were lower in regions of injury. There is strong evidence for the
role of VEGF in pre-clinical models [179] and it is possible that the practical limitations of moni-
toring in patients that prevented obtaining microdialysis samples prior to 24h from injury missed
acute increases in VEGF (and other cytokines and chemokines) in pericontusional brain within
hours of injury.
Nitric oxide has also been shown to be involved in the signalling cascade that leads to MMP-
9 activation, and also has pleiotropic effects amongst numerous other pathways during normal
physiology and following injury. Again using samples from targeted pericontusional microdial-
ysis with paired control samples, in this study the combined concentration of NOx (NO2 and
NO3 metabolites) was slightly higher in the non-injured brain and displayed very similar tem-
poral profiles at both monitoring sites. There was a positive association between NOx at energy
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molecules including glucose, pyruvate, and lactate within both injured and non-injured brain,
but the increase in lactate, and consequently LPR, was more pronounced in pericontusional tis-
sue. This finding suggests that while concentrations of NO may be similar at different sites its
effects may be heterogenous.
9.1.4 Inter-relatonships between energy molecules
Glucose, puryvate, lactate, and the lactate/pyruvate ratio, are the primary parameters that are
utilised for clinical microdialysis monitoring. Previous studies have highlighted that summary
measures of glucose, lactate, and LPR all have relationships with outcome and are more deranged
within perilesional tissue [172, 173]. However, there has been relatively little study of the raw
hourly data to examine the temporal course of metabolic dysfunction and relationships between
modifiable parameters, i.e. cerebral perfusion pressure, glucose, and oxygenation, to inform how
these might be optimised to improve and normalise LPR and cerebral metabolism. In this study,
LPR was shown to be most abnormal in the first 48-72h following injury, emphasising again that
it is within this time period that the key events of secondary injury occur. Non-parametric regres-
sion with generalised additive mixed models, allowing for random effects between patients and
accounting for the strong autocorrelation within patient time series, showed strongly non-linear
associations between LPR and glucose, CPP, PRx, and PbtO2. The importance of these results is
that they immediately indicate thresholds for the respective parameters that could be targeted
stepwise at the bedside to improve LPR. Moreover, brain glucose showed the strongest associa-
tion with LPR suggesting that supplementing this substrate may be the first choice intervention
in a patient with elevated LPR. The relationship between pyruvate and lactate within individ-
ual patients was found to be approximately linear, in accordance with expected kinetics of these
molecules at equilibrium. However, the parameters of the linear relationship varied significantly
between patients and with it the likelihood of LPR elevating above 25. Taking these results to-
gether suggests a classification of normal and disturbed metabolism into four states based on LPR
< or >25 and brain glucose > or < 1mM and provides a conceptual framework to tailor interven-
tions to correct metabolism specific to each circumstance.
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9.2 General limitations
The studies described in this work have each been observational and extrapolation from correl-
ative findings to mechanistic implications must be made with caution. However, the findings of
pro-inflammatory cytokine and chemokine expression, and elevated MMP-9, in pericontusional
brain are consistent with the body of in vitro, pre-clinical, and human in vivo studies, supporting
the contention that these mediators are important in lesion progression and the development of
brain swelling. Microdialysis is inherently a local monitor and there is a potential confounder of
injury induced by insertion of the catheter into the brain. This study has addressed both these
issues where possible by using two catheters to provide paired control data from pericontusional
and radiologically normal brain. This approach was not associated with any complications for the
enrolled patients but does present additional burdens in system maintenance and sample man-
agement that need to be considered. In the study of microdialysis data gathered from patients
treated for TBI over twenty years there was inherently great heterogeneity in duration of mon-
itoring, extent of missing microdialysis data, and availability of data from additional monitors
(e.g. PbtO2). To mitigate these challenges and draw out reliable findings the statistical analysis
was designed to impute missing data where appropriate, to use the full statistical power of the
hourly data whenever possible, and to take account of the specific characteristics of this type of
physiological data, namely autocorrelation, together with random effects for individual patients.
9.3 Future Directions
9.3.1 Preventing Contusion Expansion and Oedema
Although the imaging technique employed in this work did not demonstrate BBB permeability
associated with brain contusions, there was strong evidence indicating elevated expression of
MMP-9 in pericontusional tissue. It remains possible that the VEGF-MMP-9 axis characterised
in pre-clinical models is a major signalling pathway in human TBI. There are a number of exist-
ing pharmaceuticals that target this pathway that have been introduced for other pathologies. A
monoclonal antibody directed at VEGF (Bevacizumab), primarily used for treatment of various
cancers and macular degeneration, has been shown to rapidly reduce vasogenic oedema associ-
ated with intrinsic brain tumours such as glioblastoma in clinical trials [51, 90]. A pilot study of
this agent in patients with contusional TBI, using contusion volume progression as the primary
outcome, would be the logical next step.
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Assuming MMP-9 is the common end effector of BBB disruption of multiple upstream activation
pathways, an alternative option for interventional studies would be targeting MMP-9 directly.
There are no specific inhibitors currently available but the antibiotic doxycycline does have some
inhibitory activity against the enzyme and would be option for a preliminary mechanistic study
[157]. A further option to develop more sensitive endpoints for these initial interventional studies
would be developing suitable assays to quantify MMP-9 activity and the concentrations of tight
junction proteins such as occludin and claudin in microdialysate.
9.3.2 Improving Cerebral Metabolism in TBI
Since the introduction of clinical microdialysis into the armamentarium of neuro-intensive care
there has been much debate as to whether the metabolic parameters should form the basis of ther-
apeutic targets, and if so which interventions should be used. The findings of the present study
inform a hierarchical approach and natural targets to systematically try and correct LPR. The
priorities in such a protocol would be ensuring adequate brain glucose by modifying systemic
glycaemic control and potentially supplementation with intravenous boluses of glucose, aiming
to maintain CPP within the individual’s autoregulatory range (e.g. targeting optimal CPP [47]),
and maintaining cerebral oxygenation. Designing a clinical study that can demonstrate efficacy
of a care protocol comprising multiple interventions presents a number of challenges particularly
when the magnitude of the marginal benefit of improving LPR on neurological outcome is uncer-
tain. Identifying a good surrogate of clinical outcome, such as an imaging measure of neuronal
loss, would be an alternative approach.
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